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Niketa Skye Ferguson 
Characterisation of the Pharmacological Mechanisms and Potential Therapeutic 
uses of FK866 
The finding that NAD+ plays a role in a variety of signalling pathways, including 
gene expression, Ca2+ signalling and DNA repair mechanisms, has sparked 
interest in the proteins involved in these pathways as potential pharmacological 
targets for drug development. Recently, FK866, a potent inhibitor of 
nicotinamide phosphoribosyltransferase (Nampt) an important enzyme in the 
NAD+ rescue pathway, has been evaluated in clinical trials against cancer.  The 
aim of this study is to further investigate the mechanisms and therapeutic 
characteristics of FK866 in different cancer cell lines and to determine if 
decreasing intracellular NAD+ levels can be used as a co-therapy strategy to 
improve the efficacy of current and new chemotherapy treatments.  
 
Experiments measuring cell vitality showed that FK866 dose-dependently 
decreased cell vitality. To investigate NAD+ consumption during Nampt 
inhibition, NAD+ levels were measured in cells treated with FK866 and inhibition 
of each of the main NAD+ consuming enzymes (PARP, sirtuins or CD38). This 
revealed differential NAD+ consumption rates by the different NAD+ consuming 
enzymes in MDA-MB-231 cells, with sirtuins being the major NAD+ consuming 
enzyme. The glycolytic effects of Nampt inhibition was measured using 
SEAHORSE assays; which measured the oxygen consumption and 
extracellular acidification rates as well as measuring NAD+/ NADH ratios. In the 
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MCF-7 and MDA-MB-231 cell lines, FK866 had no effect on the oxygen 
consumption rates; however there was a general decrease in extracellular 
acidification rates indicating an effect on glycolytic activity. When measuring the 
NAD+/NADH ratio however, there was only a decrease in the MDA-MB-231 
cells but no change in the MCF-7 cell line. Cell vitality and NAD+ levels were 
measured after treatment with FK866 in addition to NAD+ consuming enzyme 
inhibitors or the alkylating agent, Temozolomide to see if combination therapy 
would have more cytotoxic potential.  This co-treatment indicated that there was 
no real positive effect on either the MCF-7 or MDA-MB-231 cells in either the 
cell vitality or NAD+ levels. Finally the effects of FK866 and the oral PARP 
inhibitor, Olaparib, were investigated using 3D cell culture (spheroids) and 
compared with 2D monolayer cultures. The effects of FK866 showed little 
difference in spheroid or monolayer culture. However, when treating with 
Olaparib there was higher level of cell viability and NAD+ levels with the cells 
grown in spheroid culture in comparison to cells grown in monolayer. In 
conclusion, this study has shown that FK866, as a single treatment decreases 
cell vitality, NAD+ levels and glycolytic activity. However as a co-therapy with 
PARP or Sirtuin inhibitors there is an increase in the cell vitality and NAD+ levels. 
Although similarities have been seen between spheroid culture and monolayers 
as a single treatment, FK866 does not seem to have the beneficial effects as a 
therapeutic. 
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Chapter 1: Introduction 
Nicotinamide adenine dinucleotide (NAD+) is a co-enzyme which can be found in all 
living organisms (Figure 1.1). It is a dinucleotide where one nucleotide contains an 
adenine base and the other contains nicotinamide. It was originally discovered by 
Arthur Holden and William Youndin in 1906 (Manchester 2000), although Otto 
Heinrich Warburg identified nicotinamide at the active site of redox reactions as well 
as the function of NAD+ in hydride transferase in 1936 (Warburg 2010). Due to the 
connections that NAD+ has with most metabolic pathways such as adenine 
diphosphate (ADP)-ribosylation, the release of calcium from intracellular supplies of 
NAD+(P) derivatives, the control of calcium ion influx by ADPR/TRPM2 as well as NAD+ 
dependent protein deacetylation, NAD+ is now considered a universal energy and 
signal carrying molecule (Berger et al., 2004). Metabolising enzymes and targets, both 
for extracellular NAD+ and its metabolites are constantly being identified. 
 
Figure 1.1: Chemical structure of Nicotinamide adenine dinucleotide (NAD
+
) 
The synthesis of NAD+ is essential for all living organisms, although the biosynthesis 
was thought to be of little importance for a long time because hydrogen transfer 
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reactions were not thought to involve the consumption of pyridine nucleotides. 
Signalling pathways that are dependent on NAD+ have the N-glycosidic bond which 
cleaves between the ADP-moiety and nicotinamide. The enzymatic processes of 
catalysing NAD+ synthesis have been known for decades however it has only been in 
the past 14 years that the eukaryotic enzymes, which are involved in the NAD+ 
synthesis pathway have been recognised (Emmanuelli et al., 1999).Tryptophan, 
nicotinate, nicotinamide and nicotinamide riboside are used to produce dinucleotides 
such as NAD+ or NAAD by nicotinamide mononucleotide adenyltransferase (NMNAT) 
where NAAD is converted to NAD+ by NAD+ synthase (Wei et al., 2008) (Figure 1.2). 
NMNATs are important because they catalyse the final step of the biosynthesis of 
NAD+. There have been three isoforms of this enzymes, the first was found to be 
localised to the nucleus (Emmanuelli et al., 2001), while the other two were found in 
the cytosol although the third is also located in the mitochondria (Zhang et al., 2003). 
Figure 1.2: NAD
+
 synthesis pathway (Wei et al., 2008) 
1.1 Nicotinamide phosphoribosyltransferase (Nampt) and Nampt 
inhibition 
Nicotinamide phosphoribosyltransferase (Nampt) is a rate limiting enzyme which 
converts nicotinamide (NAM) to nicotinamide mononucleotide (NMN) during the 
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recycling of NAD+. Nampt is normally up-regulated in malignant tumour cells to 
preserve the levels of NAD+ (Hasmann and Schemainda 2003; Hufton et al., 1999; 
Gehrke et al., 2014; Sociali et al., 2016). As it is involved in the NAD+ recycling pathway 
it means that by inhibiting Nampt, the levels of NAD+ will be affected therefore making 
them targets for new cancer therapies as there are increased levels of NAD+ in tumour 
cells (Khan et al., 2007; Billington et al., 2008; Sampath et al., 2015). FK866 (Figure 1.3) 
is an anticancer agent that has been shown to disrupt NAD+ biosynthesis by inhibiting 
Nampt. This leads to the depletion of intracellular NAD+ which can result in cell death 
(Wosikowski et al.,2002). There has also been a decrease in nicotinamide 
mononucleotide adenyltransferase (NMNAT) shown in cells after being treated with 
FK866 (Boulton et al., 1997). Studies on cancer cell lines exposed to FK866 resulted in a 
slow progressing type of cell death due to the reduction of NAD+ (Bruzzone et al., 2009; 
Hasmann and Scheimanda 2003; Nahimana et al., 2009). FK866 is not cell cycle 
dependent so therefore is not subject to multi-drug resistance (Holen et al., 2008). 
FK866 has successfully completed phase 1 of clinical trials and is currently going 
through phase 2 trials for cancer chemotherapy in T-cell and B-cell lymphoma 
(ClinicalTrials.gov Identifier: NCT00431912; ClinicalTrials.gov Identifier: NCT00435084) 
as well as advanced cutaneous melanoma (ClinicalTrials.gov Identifier: NCT00432107) 
(Pittelli et al., 2010; Gehrke et al., 2014). 
 
 
Figure 1.3: Chemical Structure of FK866 
FK866 can induce cell death by competitively binding to the nicotinamide binding site 
and inhibiting Nampt (Holen et al., 2008; Gehrke et al., 2014). During pre-clinical trials, 
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it showed to have a high anti-tumour activity on a variety of tumour cells in vitro and 
has been seen to cause delayed cell death which demonstrates characteristics of 
autophagy (Billington et al., 2008). Autophagy is suggested to be a last chance survival 
mechanism, which is brought about by cells being denied nutrients, therefore they 
begin to self-digest to gain energy and amino-acids to make up for metabolic 
inadequacies (Gozuacik and Kimchi 2007). However in cancer cells where apoptosis is 
unavailable because of the anti-proliferative control, autophagy can be seen as a 
second type of programmed cell death. When NAD+ levels are decreased, this energy 
saving response is expected due to NAD+ being an important part of glycolysis, the 
Kreb’s cycle and lipid-β-oxidation. FK866 can encourage a decrease in NAD+ levels 
without DNA damage and poly (ADP-ribose) polymerase (PARP) activation (Alano et al., 
2004). The depletion of NAD+ can lead to PARP-induced cell death which could be 
linked to autophagy as this would be due to the reduction of NAD+ levels 
 
1.2 Poly (ADP-ribose) polymerase (PARP) 
Poly (ADP-ribose) polymerase (PARP) is a major factor in DNA repair in eukaryotic cells 
to deal with different environmental and endogenous genotoxic agents. The DNA 
damage can occur either directly, such as ionising radiation and alkylating agents, or 
indirectly after an enzymatic incision of a DNA lesion. This can set off an acute cellular 
response accompanied by the synthesis of poly(ADP-ribose) (PAR) by PARP. PARP-1 
(Figure 1.4 a) is a nuclear zinc-finger binding protein which can detect and signal DNA 
breaks. At the site of a break, it can catalyse the transfer of ADP-ribose moiety from 
NAD+ to the nuclear protein acceptors in a DNA dependent way. Poly (ADP-ribosylated) 
proteins play a part in chromatin structure and in DNA metabolism. They can lose their 
affinity for DNA because of the negative charges of ADP-ribose polymers and therefore 
are inactivated following genotoxic stress (D-Amours et al., 1999). PARP and the 
proteins return to their normal state by poly (ADP-ribose) glycohydrolase. The nuclear 
proteins which are induced by DNA lesions during poly (ADP-ribosylation can be by 
base excursion repair (BER) pathway (Shall and de Murcia 2000). 
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The main characteristics of the activity of PARP are the recognition and translations of 
the signals from the DNA as well as amplifying the formation of poly (ADP-ribose) 
(PAR). PARP-1 is a multi-functional enzyme which consists of four main regions; N-
terminal DNA—binding domain (DBD) with 2 zinc fingers which behaves as a molecular 
nick sensor as well as an interface with protein partners; a nuclear location signal 
which can be interrupted by the caspase3 cleavage, which contains a BCRA1 Terminus 
domain (BRCT) motif which is involved in the protein to protein interactions. This 
region also contains sites involved in the negative regulation of PARP-DNA interaction; 
a C-terminal catalytic domain which includes a donor site (NAD+ binding) which is 
similar to the active site of mono-ADP ribosylating toxins. This domain is responsible 
for the nick-binding dependent PAR synthesis (Shall and de Murcia 2000). PARP-1 
metabolises NAD+ to form branched ADP-ribose, which are then transferred to the 
nuclear proteins such as DNA polymerase 1 and 2. It has been suggested that poly-
ADP-ribosylation plays a part in genome repair. This is because it modifies the 
architectural proteins close to DNA breaks which assist the opening of condensed 
structures of chromatins required for the repairing complex (D’Amours et al., 1999). 
However, by depleting the NAD+ levels, PARP-1 can also induce cell death. 
Although there are 17 known PARP enzymes only PARP-1 and PARP-2 (Figure 1.4 b) are 
known to be activated by DNA strand breaks (Besson 2009, Audeh 2014). PARP-2 is 
DNA dependent and catalyses the formation of ADP-ribose polymers (Ame et al., 1999). 
Unlike PARP-1, PARP-2 does not contain a zinc finger although it does have a highly 
basic DNA binding domain as well as nuclear and nucleolar localisation signals. The 
binding domains of PARP-1 and PARP-2 are structurally different and PARP-2 does not 
bind as efficiently to DNA strand breaks as PARP-1 but recognises gap and flap 
structures (Yelamos et al., 2011). 
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Figure 1.4: Structure of a) PARP-1 and b) PARP-2 
Inhibitors of PARP-1 have therapeutic efficacy in experimental models of diabetes 
(Burkart et al., 1999), inflammation (Szabo 1998), shock (Liaubet et al., 2000) and 
breast tumours (Audeh 2014). There are three ways of inhibiting PARP-1 functions; 1) 
removing PARP-1 protein from the system, for example using knockout animals and 
gene silencing in cell culture models. This leads to the loss of PARP-1 and therefore 
DNA interactions, protein: protein interactions as well as the loss of catalytic activity. 2) 
By competitively inhibiting PARP-1 the polymer synthesis can be removed, however, 
PARP-1 can still be involved in the DNA binding and the protein to protein interactions 
although this can be more disruptive to the cell than the first method of inhibition. 
Neither of these two methods shows any effect on the NAD+ levels. 3) The final 
method of inhibition is the depletion of NAD+. This can be similar to competitive 
inhibition by making PARP-1 inactive, therefore inhibiting repair, replication and 
transcription processes. This also has effects on other NAD+ utilising reactions such as 
glycolysis, apoptotic signalling and sirtuin function (Kirkland 2010). 
PARP-1 inhibitors have been used for treatment of advanced cancers in clinical trials 
(Peralta-Leal et al., 2009). In cancer therapies, the mechanisms are different from 
other treatment models. The most common method, which seems to be the most 
effective, is targeting cells with deficiencies in BRCA1 and BRCA2 since this means that 
the cells have issues with double stand break repair. By inhibiting PARP-1, the repair of 
single strand DNA breaks is also inhibited, leading to persistent single strand breaks 
which can develop to double strand breaks through stalled replication forks. Double 
stranded breaks can become lethal to the cells due to the lack of BRCAs. This 
 
a  b  
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treatment has shown the potential for a monotherapy as seen in clinical trials (Drew 
and Plummer 2009). During clinical trials, PARP-1 inhibitors and genotoxic drugs were 
combined when treating non-BRCA cancers. It was found that this has a dose-limiting 
myelosuppression (Drew and Plummer 2009). It was seen in animal models that 
defected PARP-1 function and lower niacin levels can increase myelosuppression and 
the development of leukaemias (Kirkland 2009b). Previously nicotinamide has been 
used to inhibit PARP-1 during chemotherapy treatments; unfortunately this was 
converted to NAD+ particularly in the animal models (Kirkland 2009a). It could be 
possible for nicotinamide to increase PARP-1 activity and prevent NAD+ depletion 
which could make it an advantage to supplement with nicotinamide in many in vivo 
models (Kirkland 2009a). 
 
1.3 Sirtuins 
Sirtuins are NAD+ dependent histone deacetylases (HDAC) which have begun to be 
acknowledged to be important in cancer cells (Moore et al., 2012). The Sir2 protein 
was first found in Sacchromyces Cerevisae and was identified by its role in 
transcriptional silencing of mating-type loci of the yeast (Frye 1999). Sirtuins roles in 
aging were originally found in yeast by a model of a similar lifespan. This model 
measured the number of times a yeast mother cell produced a daughter cell before 
senescing (Fry 2000). This discovery has encouraged studies into mammalian sirtuins. 
There are seven mammalian sirtuins, SIRT1-7, which are categorised by their ability to 
bind with NAD+ and their catalytic domain which is also known as the sirtuin core 
domain (Frye 2000). Although they can be conserved, the N and C termini are different, 
as well as differing in biological functions due to 1: enzymatic activities; 2: different 
binding partners as well as substrates and finally 3: the subcellular localisation as well 
as the pattern of expression. (Frye 2000; Moore et al., 2012). 
Most sirtuins catalyse NAD+-dependent deacetylation although Sirt4 is an NAD+-
dependent mono-ADP-ribosyltransferase activity (Haigis et al., 2006; Liszt et al., 2005). 
Sirt1 and Sirt6 are both auto-ADP-ribosyltransferase as well as specific deacetylase 
activities (Michishita et al., 2008). Sirtuins deacetylate modified lysine residues by 
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enzymatic processes that utilise NAD+ cleavage with each reaction cycle (Suave et al., 
2001). This makes sirtuin activity different from other histone deacetylases that 
hydrolyse acetyl-lysine residues due to sirtuins being intimately tied to the metabolism 
of the cells. The deacetylation by sirtuins begins with the cleavage of an amide from 
NAD+ forming NAM as well as a covalent ADP-ribose peptide-imidate intermediate. 
This intermediate is then catalysed to form O-acetyl-ADP-ribose and deacetylated 
substrate (Figure 1.5) (Schmidt et al., 2004; Borra et al., 2004). The driving force of the 
sirtuin reaction relies on the hydrolysis of NAD+. This reaction therefore has an effect 
on cellular processes such as DNA repair, metabolism, cell survival, cell proliferation 
and senescence. 
 
Figure 1.5: The mechanism of deacetylation of protein by sirtuins using NAD
+ 
Sirt1 is involved in both cell survival and cell death, which can be can be stimulated in 
different directions. One of the most effective ways to prevent cancer is energy 
restriction which has been seen in both rodents and primates. Sirt1 and Sirt3 exhibit 
survival functions, which could show that they promote tumourigenesis (Brooks and 
Gu 2009). Most evidence indicates that Sirt1 is an oncogene, which started with the 
identification of the Sirt1 substrate; tumour suppressor p53 (Luo et al., 2001; Vaziri et 
al., 2001). This is implied by the deacetylation of lysine on p53 by Sirt1, allowing the 
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cells to avoid p53 mediated apoptosis. Sirt1 also plays an important part in DNA repair 
as well as preventing tumourigenesis in mouse models. Sirt1 transgenic mice have 
been seen to live longer in leukaemia and colon cancer models (Deng 2009). When 
compared with normal tissues it has been seen that Sirt1 is overexpressed in different 
cancer types such as colon, skin, breast and prostate cancers (Zhang et al., 2009). 
However Wang et al., 2008 found that Sirt1 mRNA was reduced in cancers that have 
BRCA mutations compared with cancers with normal BRCA1. This indicates that there 
is a positive correlation between Sirt1 expression and BRCA1 which was confirmed via 
immunohistochemical staining in 45 human breast cancer samples (Wang et al., 2008). 
1.4 CD38 
CD38 is a multifunctional enzyme which generates a wide variety of biologically active 
compound using NAD+ as a substrate such as the synthesis and hydrolysis of cyclic 
ADPR as well as a Ca2+ mobilising agent (Billington et al., 2006). It seems to be more 
effective in degrading NAD+ than ADPR which has stimulated the theory that CD38 
could also be a regulator of external NAD+ levels (Aksoy et al., 2006). A deficiency in 
CD38 has also been shown to accelerate an autoimmune disease in an ART2-
dependent manner in NOD mouse model for type-1 diabetes. CD38 knockout mice 
have been seen to develop a more aggressive and rapid disease progression than the 
wild type (Chen et al., 2006). 
1.5 Breast Cancer 
According to the world health organisation 2014, breast cancer is the fifth leading 
cause of death in women as well as being the number one cause of death from cancer 
in women aged 20-59 years. The major problem is that although breast cancers can 
initially respond to therapy they develop resistance to chemotherapy, radiotherapy 
and biological therapies. There has been evidence to suggest that breast cancer is a 
group of diseases as opposed to a single disease which is encouraging scientists to 
rethink therapeutic strategies for breast cancer (Zhao et al., 2011). Individuals that 
have mutations in BRCA1 which is a breast cancer susceptibility gene, show an 
increased risk of developing breast cancer by 80% (Ford et al., 1998). Mutations in the 
breast cancer susceptibility genes (BRCA1 and BRCA2) account for an estimated 5-10% 
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of breast cancer cases (Schwartz et al.2008). Although less than 1% of the general 
population seem to have these mutations, it does seem that it occurs more in certain 
ethnic groups for example Eastern European Jewish decent. The risks of women with 
these mutations to develop breast cancer can vary. BRCA1 mutations show between 
44 and 78% of women with this mutation will develop breast cancer whereas BRCA2 
see between 31 and 56% of women developing breast cancer (Antoniou et al., 2003; 
Chen and Parmigiani 2007). In terms of familial traits of breast cancer only 15 to 20% 
can be attributed to BRCA1 and BRCA2 mutations (American Cancer Society, 2013). 
In this study, MDA-MB-231 and MCF-7 cell lines were selected as cell models. MDA-
MB-231 is a triple negative cell line which means that there are no receptors of 
estrogen, progesterone or HER2. These cells are insensitive to some of the most 
effective therapies available for breast cancer treatment such as trastuzumab and 
endocrine therapies. MCF-7 is a human breast adenocarcinoma cell line which was 
developed from a pleural effusion from a patient with metastatic breast cancer 
(Levenson and Jordan 1997). It was originally taken in 1970 from a 69 year old 
Caucasian woman. MCF-7 cells are estrogen and progesterone positive unlike MDA-
MB-231. 
FK866 has been well documented and is currently in clinical trials for leukaemia, 
however very little research has been made in breast cancer cell lines. Due to the high 
level of BRCA mutations, PARP is one of the main enzymes for DNA repair. As PARP is 
an NAD+ consuming enzyme then by inhibition of Nampt by FK866 would therefore 
reduce the levels of NAD+ available to PARP for repair of DNA. FK866 has also been 
used as a single agent in cell cancer lines however it may have more of an effect on cell 
metabolism and cell viability if used as a co-therapy with other inhibitors of NAD+ 
consuming enzymes. 
 
1.6 Hypothesis 
NAD+ has long been thought of as a simple redox co-factor which is only involved in the 
fundamental reactions of basic metabolism such as glycolysis. However, it has been 
shown that NAD+ plays a more important role in a variety of signalling pathways such 
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as gene expression, Ca2+ signalling, post-translational modification of proteins and DNA 
repair (PARP, ADP-ribosyl transferases (ARTs)), CD38 metabolites or sirtuins. These 
findings have sparked an interest in the proteins involved in these signalling pathways 
as potential pharmacological targets for enzymes such as Nampt, PARP and Sirtuins; 
and number of drugs with diverse mechanisms of action is now in clinical trials. The 
hypothesis, to be tested here, is that decreasing intracellular NAD+ levels can be used 
as a co-therapy strategy to increase the efficacy of current and new chemotherapy 
treatments. The theory is that decreasing NAD+, and thus ATP, concentrations will 
increase the efficacy of the drugs that normally compete with ATP/NAD+ for binding 
sites on target enzymes (eg PARP or sirtuins). It is hypothesised that by inhibiting NAD+ 
levels and treating with current chemotherapeutics, there will be a higher level of 
cellular cytotoxicity. 
 
1.7 Aims 
The overall aim of this project was to investigate the mechanisms and therapeutic 
characteristics of FK866. This was achieved via the following objectives: 
1. To investigate the effects of FK866 on respiration and metabolism in breast cancer 
cell lines, due to the role of NAD+ in glycolysis. This was achieved by measuring oxygen 
consumption rates, glycolytic activity via extracellular acidification rates and NAD+/ 
NADH ratios 
2. To investigate NAD+ consumption in the cells treated with FK866 and identification 
of the major NAD+ consuming enzymes (CD38, PARP-1 and Sirt1) during Nampt 
inhibition. 
3. To investigate cell vitality and NAD+ levels during co-therapy with pre-treatment of 
FK866 for 8 hours followed by treatment for either 2 or 3 days with a current or new 
chemotherapy treatments including PARP and Sirtuin inhibitors.  
4. To assess if growing breast cancer cells as 3D cultures (spheroids) alters their 
response to treatment with FK866 or PARP inhibitors (Olaparib) as assessed in the 
objectives above. 
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Chapter 2: Methods 
2.1 Cell Cultures 
The two adherent cell lines used were MDA-MB-231 and MCF-7. MDA-MB-231 is a 
triple negative epithelial cell line from European Collection of Cell Cultures (ECACC). 
This cell line is cultured in Leboivitz L-15 medium (Lonza) with 10% heat-inactivated 
FBS (Lonza) and 2 mM L-glutamine (Lonza), incubated at 37°C for 3 days between 
subcultures. When subcultured, the cells are washed with PBS (Lonza) and trysinised 
with trypsin/versene (Lonza) before being counted and seeded at 2.5x105 cells/ ml as 
recommended by ECACC. MCF-7s are an epithelial cell line which was received from 
the University of West England. These were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Lonza) with 10% heat-inactivated FBS and 2 mM L-glutamine in the 
presence of 5% CO2 and incubated at 37°C for 3 days between subcultures. When 
subcultured, the cells are washed with PBS and trysinised with trypsin/versene before 
being counted and seeded at 2.5x105 cells/ ml as recommended by ECACC. When 
running experimental procedures these cells were grown at 6x104 cells/ml in 24 well 
plates (Corning). 
2.2 Treatments 
The cells were treated with FK866 (Axon) at final concentrations varying from 1 nM to 
300 nM. These were prepared in DMSO (Sigma Aldrich) and therefore the control was 
DMSO. 
The other treatments used include PARP inhibitors 4-Amino-1,8-naphthalimide (NPH) 
(Sigma Aldrich) and Olaparib (Stratech); Sirtuin inhibitor Sirtinol (Sigma Aldrich); CD38 
inhibitor Kuromanin (Sigma Aldrich); and methylating agent Temozolomide (Sigma 
Aldrich). All of these treatments were made up to varying concentrations from 100 nM 
to 100 µM. All were prepared in DMSO apart from Kuromanin which was prepared in 
PBS (Melford). The controls for each of these were the solution it was prepared in. 
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2.3 MTT assay 
The MTT assay was used to test cell vitality in the presence of the cytotoxic drugs. It is 
a colourmetric assay which measures the reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Melford) into an insoluble formazan produced by 
the mitochondria of viable cells. This assay is designed to measure cell vitality; this 
varies from viability by measuring the activity of the mitochondria which differs from 
viability which shows the total cells that are alive.  
0.12M of MTT solution was added to 900 µl of PBS with cells adhered to the plate at a 
seeding density of 6x104 cells per well. The plate was incubated for 2.5 hours at 37°C 
until a blue/brown precipitate was observed in the bottom of the wells. This converted 
dye was solubilised with 1 ml dimethyl sulfoxide (DMSO) (Sigma), and absorbance was 
measured at 540 nm using an Omega plate reader. 
The blank was medium only with the MTT and DMSO, where the control was cells 
which had received no treatment. There were two repeats per plate of each drug 
concentration, control and blank. The cell vitality was then calculated as a percentage 
of the control. 
2.4 NAD+ cycling assay 
NAD+ cycling assay is used to determine the µM concentration of NAD+ per cell. This 
will essentially show whether the drugs which are being used have any effect on the 
levels of NAD+ produced. The protocol has been modified from Leonardo et al., 1996. 
Cells were centrifuged at 1200 rpm for 5 minutes and the medium was removed. PBS 
was added to break each of the cell pellets. A cell count was performed using a 
haemocytometer and Trypan blue. The cell density was adjusted to 1x106 cells/ml, 
before 1 ml of cell suspension was centrifuged at 15000 rpm for 2 minutes and the 
supernatant discarded. Pellets were immediately frozen in a dry-ice ethanol bath, 
dissolved in 250 µl 0.2 M HCl, and heated at 100°C for 10 minutes before being 
centrifuged again at 13000 rpm for 5 minutes to remove cell debris. This supernatant 
was stored at -20°C until use in the assay. The pellet was discarded.  
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The cycling mixture consisted of; 0.13 M Bicine, 2.16 mM Phenazine ethosulfate (PES), 
2.04 mM Ethylenediaminetetraacetic acid (EDTA), 0.55 mM Thiazolyl blue (MTT) and 
29.6% absolute ethanol, as well as 3 mM NaOH and 5 µl ADH per well. The standards 
were prepared at 0, 5 µM, 10 µM, 20 µM, 30 µM, 40 µM, 50 µM and 60 µM of NAD+ by 
dissolving NAD+ (Melford) in PBS and then again in 0.2M HCl. Along with the cycling 
mixture, 49 µl of sample or standard was added to each well and the plate was 
incubated at room temperature in the dark for 30 minutes. The absorbance was 
measured in a 96 well plate reader at 565 nm. From the standard curve, the 
concentration of NAD+ per cell was then calculated. 
2.5 NADH cycling assay 
The NADH extraction was begun by the cells being washed and the 200 µl of trypsin to 
lift the cells from the plate. They were then centrifuged at 800 rpm for 5 minutes to 
remove the medium. The cells were resuspended in 1ml PBS to wash the cells. The 
cells were counted using a haemocytometer and then centrifuged again to remove the 
PBS before the pellets were frozen for one hour at -80°C. The pellets were broken up 
with 250 µl 0.2M NaOH and then heated at 100°C for 10 minutes. The samples were 
centrifuged at 1300 rpm for 5 minutes and the supernatant was saved for the NADH 
assay. The pellet was discarded. 
The NADH standard curve was set up at concentrations of 5, 10 20, 30, 40, 50, and 60 
mM. They were prepared from synthesized NADH (Melford) and were dissolved in PBS. 
20 µl of this was then taken and added to 250 µl 0.2 M NaOH (Sigma). The cyclic buffer 
consisted of 19.6 µl of 1M Bicine (pH 8.0), 16. mM PES (Sigma), 4.2 mM MTT (Melford), 
absolute ethanol and EDTA (pH 8.0) as well as 48 µl 0.1 M HCl and 5 µl ADH (400U/ml) 
dissolved in 0.1 M Bicine (pH 8.0). 151 µl of the cyclic mixture was added to 49 µl of 
either sample or standard curve and the plate was incubated for 30 minutes before 
being read in the plate reader at 565 nm. The results were then calculated using the 
standard curve to a value of nM per 1x106 cells. 
2.6 Seahorse Experimental Procedure 
The sensor cartridge was hydrated overnight in PBS (Seahorse Bioscience) prior to the 
assay. The cells were treated for 24 hours before being was with PBS twice. They were 
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them treated with base medium (0.8 mM MgSO4, 1.8 mM CaCl2, 143 mM NaCl, 5.4 mM 
KCl and NaH2PO4). The sensor cartridge was loaded with 1 M Glucose, 5 mg/ml 
Oligomycin, which inhibits ATP synthase, 2 mM Antimycin A, which binds to the Qi site 
of cytochrome c reductase, and 3 mM Rotenone, which interferes with the electron 
transport chain in mitochondria, together, and 100 mM 2-deoxy-D-Glucose (2-DG), 
which inhibits glycolysis, into each of the 4 ports. The Seahorse XF24 was then 
calibrated and the assay was run taking 5 reading after each port was injected. Each 
loop consists of Mix for 1 minute, time delay for 2 minutes and then measure for 3 
minutes. 
The measurements were analysed by taking the averages of basal OCR, Glucose 
stimulated OCR, Oligomycin O and Rotenone/Antimycin A OCR. The coupling efficiency 
of glucose-stimulated respiration was calculated by 1-((oligomycin-rotenone/antimycin 
A)/(Glucose-rotenone/antimycin A)). The stimulation of basal OCR by glucose was 
calculated by (Glucose-Rotenone/Antimycin A)/(basal-rotenone/Antimycin A). 
Oligomycin insensitivity is normalised to glucose OCR and was calculated by 
(oligomycin-rotenone/antimycin A)/(glucose-rotenone/Antimycin A). Finally the final 
OCR calculation was to measure the non-mitochondrial OCR which is a fraction of basal 
which is calculated by rotenone/Antimycin A / basal. The ECAR parameters were 
calculated, the first calculation was glucose stimulated ECAR (glucose-2DG)/(basal-
2DG). Stimulation of basal ECAR by oligomycin was calculated by (Oligomycin-
2DG)/(basal-2DG). The spare glycolytic capacity was calculated by (oligomycin-
2DG)/Glucose-2DG). Finally the non-glycolytic ECAR was measured by 2DG/basal.  
2.7 Plate preparation for Spheroids 
The protocol used was adapted from Nagelkerke et al., 2013 and Baron et al., 2012. 
Poly-hydroxyethylmethacrylate (P-HEMA) was prepared to 0.5% (wt/vol) in 95% 
ethanol. This was left on a shaking apparatus for 4 hours at room temperature to 
ensure all P-HEMA was dissolved. 96 well V-shaped plates were then treated with 50 µl 
of P-HEMA per well under sterile conditions. The p-HEMA treated plates were then left 
for 3 days in sterile conditions for the ethanol to evaporate leaving the plates evenly 
coated in P-HEMA. Once the ethanol was evaporated the plates were sealed with 
parafilm and wrapped in foil before being stored at 2°C until use. 
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2.8 Spheroid formations 
Once the ethanol has evaporated from the plates, 1x104 cells were added to each well. 
The MCF-7 cells were added in DMEM alone and were centrifuged in the plates at 
1000 x g for 10 minutes. They were then left in a 37°C, 5% CO2, humidified incubator 
for 24 hours to allow spheroid cultures to form. The FK866 or Olaparib treatments 
were then added to these cells for 3 days. 
MDA-MB-231 cells were added to the plates using L-15 treated with a matrix, Matrigel 
(Sigma Aldrich), at 2.5% to assist the cells to compact into a spheroid as these cells do 
not bind together without the matrix. They also then centrifuged at 1000 x g for 10 
minutes before being placed on an orbital shaking platforms set at a constant rotation 
speed of 700 RPM in a 37°C incubator for 24 hours to allow the spheroids to form. 
Treatments were then added to these cells for 3 days. 
2.9 Acid Phosphatase assay 
The buffer for the assay used to assess acid phosphatase (APH) activity contains 0.1 M 
sodium acetate (3 M stock solution, pH 5.2) and 0.1% (vol/vol) Triton X-100 in 
deionised H2O. This buffer can be stored at 4 °C for up to 4 weeks. The substrate 
solution is prepared by supplementing the assay buffer with 2 mg/ml of nitrophenyl 
phosphate (final pH 4.8) immediately before use. The substrate solution should always 
be freshly prepared and not be exposed to light.  
The plates were centrifuged at 1000 x g and the medium was removed and the cells 
were washed twice with PBS before being centrifuged at 1000 x g. Once the cells have 
been washed 100 µl of substrate solution was added to each well before the plates 
were incubated for 90 minutes at 37 °C in the dark. After the incubation period 10 µl of 
1 M NaOH was added to each well before the absorption was measured at 405 nm 
within 10 minutes. 
2.10 Statistical Analysis 
The statistical analysis performed on all the studies in this investigation was a one way 
analysis of variance (ANOVA). This was calculated using an online calculator, 
http://www.danielsoper.com/statcalc/calculator.aspx?id=43. 
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Chapter 3: The effect of FK866 on 
Glycolysis and the Mechanisms of 
NAD+ Consumption 
3.1: Introduction 
NAD+ is an essential co-factor for many enzymes involved in cellular and physiological 
processes. These include metabolism, apoptosis, DNA repair and inflammation (Imai., 
2009; Khan et al., 2007; Luk et al., 2008). NAD+ can be synthesised from tryptophan via 
the de novo pathway (Figure 3.1); (Wei et al., 2008). However; the salvage pathway, 
represents the major route to NAD+ biosynthesis in mammals (Suave., 2008; Olesen et 
al., 2010). Nampt is a rate limiting enzyme involved in the salvage pathway which 
converts Nicotinamide into NMN which is then converted to NAD+ by nicotinamide 
mononucleotide adenyltransferase (Nmnat). FK866 specifically inhibits Nampt by 
competitively binding to the Nicotinamide binding site of Nampt.  
 
Figure 3.1: The de novo pathway and salvage pathway, showing the biosynthesis of NAD
+ 
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Cancerous cells can overcome the normal need for growth factors when taking up 
nutrients by genetic mutations therefore increasing the nutrient uptake beyond the 
demands of cell growth and proliferation (Vander Heiden et al., 2009). Glycolysis is a 
metabolic pathway which converts glucose to pyruvate producing energy in the form 
of ATP. This process also involves NAD+ attaining a hydrogen ion when it is reduced via 
a redox reaction forming NADH continuing the electron transport chain. Intermediates 
which are necessary for proliferation such as ribose, glycerol and serine are produced 
in this process (Icard and Lincet, 2012). When healthy cells metabolise glucose to 
carbon dioxide via oxidation, a small amount of lactate is produced, however in most 
cancer cells, larger amounts of lactate are produced regardless of the availability of 
oxygen. It was hypothesised by Warburg that a defect in the mitochondria in cancer 
cells could result in impaired aerobic respiration and therefore the reliance on 
glycolytic metabolism (Vander Heiden et al., 2009). 
Otto Warburg conducted a series of experiment in the 1920s, which compared the rate 
of oxygen consumption and the production of lactic acid in cancerous and healthy cells. 
He discovered that although both cancerous and healthy cells produce similar amounts 
of ATP, the oxygen consumption was higher in healthy cells whereas the lactic acid 
production was higher in cancerous cells (Warburg 1956; Zu and Guppy 2004). 
Therefore the Warburg effect (as it is now known) is the metabolic change observed in 
cancer cells from oxidative phosphorylation to glycolysis as the primary source of 
cellular energy.  The centre of solid tumour masses tends to be hypoxic, which 
indicates that the cells present would rely on glycolysis (Icard and Lincet 2012). 
Increased levels of glycolysis have become the most commonly accepted and the most 
documented metabolic change for cancer cells (Moreno-Sanchez et al., 2014). This 
metabolic change also works to cause cellular response mechanisms that stem from 
the concentrations of intracellular compounds that are altered by the increased rate of 
glycolysis (Grimes et al., 2014). 
PARP, sirtuins and CD38 are all NAD+ consuming enzymes. PARP cleaves NAD+ to form 
negatively charged polymers of poly (ADP-ribose) (PAR). PARP-1 and PARP-2 enzymes 
are crucial in DNA damage response as they use the PAR polymers produced from 
NAD+ as building blocks to repair damage to DNA (Yelamos et al., 2011). Inhibiting 
31 
 
PARP can be potentially therapeutic to cancerous cells; PARP inhibitors can be 
selective for gene defective tumour cells such as BRCA1 and BRCA2 mutations. Sirtuins 
are an important family of enzymes involved in eukaryotic metabolism. Sirtuins can be 
characterised by its NAD+ dependence, as these enzymes couple the removal of acetyl 
modifications on lysine residues to the consumption of NAD+ producing NAM and O-
acetyl-ADP-ribose (Cui et al., 2015). 90% of all NAD+ase activities in humans can be 
accounted for by the production of ADPR and nicotinamide by an NAD+ glycohydrolase 
CD38 (Young et al., 2006; Vaisitti et al., 2011). It has been used as a negative 
prognostic marker for chronic lymphocytic lymphoma (CLL).  
Whilst the mechanisms of FK866 are well established, the pathways that cause 
intracellular NAD+ depletion have not been identified. Potential candidate pathways 
include: enzymes such as PARP involved in single strand DNA break repair, Sirt1, a 
NAD+ dependent histone-deacetylase involved in post-translational protein 
modification and CD38, an NAD+ glycohydrolase. In this chapter, the effect of FK866 on 
glycolytic activity, oxygen consumption and NAD+/NADH ratio was measured in both 
MDA-MB-231 and MCF-7 cells to establish if there was any adverse effect whilst 
Nampt was inhibited. As NAD+ plays an important role in glycolysis and requires Nampt 
which is involved in the salvage pathway to produce NAD+ this would indicate how 
necessary the recycling of NAD+ was to glycolysis and whether FK866 would have an 
effect on the oxidative stress and glycolytic activity. It would be hypothesised that as 
the NAD+ levels decreased the glycolytic activity would also decrease.  As well as this, 
the relative contribution of each pathway to FK866-induced NAD+ depletion was 
defined. This knowledge will help to influence decisions about which pathways might 
be suitable for pharmacological targeting together with FK866 as a co-therapy agent. 
 
3.2 Results 
3.2.1Oxygen consumption rates (OCR) 
In this chapter the Seahorse was used to measure the oxygen consumption and 
extracellular acidification rates whilst the cells were treated with FK866. The NAD+ and 
NADH levels were measured using cyclic assays. MDA-MB-231 and MCF-7 cells were 
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used in this assay. The cells used for analysing the effect of FK866 on glycolysis were 
incubated with varying concentrations of FK866 for 24 hours prior to the assays being 
run. 
OCR (oxygen consumption rate) is indicative of mitochondrial respiration and the 
changes in these rates are generally the result in changes in ATP synthesis rates that 
occur in response to the changes in ATP consumption. With the treatment of FK866 
and the inhibition of Nampt; any effect in OCR could be due to reduced pyruvate 
production and therefore NADH production. 
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Figure 3.2: The rate of oxygen consumption in both MDA-MB-231 (a) and MCF-7 (b) cells when 
treated with FK866 for 24 hrs (number of independent experiments =3, number of repeats per 
experiment =2). This bar chart shows the effect of FK866 on the coupling efficiency, the effect of FK866 
on glucose stimulation, the effect of FK866 on oligomycin insensitivity and the effect of FK866 on non-
mitochondrial oxygen consumption. 
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MDA-MB-231 (Figure 3.2 a) and MCF-7 (Figure 3.2 b) cells were treated with varying 
concentrations of FK866 over 24 hours prior to OCR being measured. MDA-MB-231 
shows a small change in the coupling efficiency of glucose stimulated respiration from 
0.77 to 0.8 pMol/min at 10nM FK866 however this change was not significant 
(p=>0.05). This was calculated by 1-((Oligomycin-rotenone/Antimycin A)/(Glucose-
rotenone/Antimycin A)0. The glucose stimulated oxygen consumption rates vary from 
0.67 to 0.77 pMoles/min however these changes are also not significant. The MCF-7 
cell line shows a coupling efficiency of glucose stimulated respiration of 0.67 
pMoles/min at 30 nM and 0.7 pMoles/min at 10 nM and 100 nM therefore there is no 
significance in comparison to the control (p=>0.05). The glucose stimulation has a 
slight increase going from 0.67 pMoles/min in the control to 0.73 pMoles/min in the 
100 nM which shows some significance between the control and 10, 30 and 100 nM 
FK866 (p=<0.05 ). Oligomycin insensitivity changes within both cell lines were 
insignificant with a change in MDA-MB-231 cells of 0.23 pMoles/min for the control to 
0.2 pMoles/min for the 1 nM and MCF-7 shows rates varying from 0.3 pMoles/min at 
10 nM and 0.33 pMoles/min at 30 nM (p=>0.05). From these results it can be seen that 
FK866 does not seem to affect the coupling efficiency, glucose stimulated oxygen 
consumption or the insensitivity to oligomycin. This indicates that there does not seem 
to be an effect on the oxygen consumption in these cells when treated with FK866. 
MDA-MB-231 had some decrease in the non-mitochondrial oxygen consumption 
around 1 and 10 nM range, where the rate dropped from 0.2 pMoles/min in the 
control to 0.05 pMoles/min for 1 nM and 0.09 pMoles/min for 10 nM; however this 
was shown to not be significant (p=>0.05). The non-mitochondrial oxygen 
consumption rates is measured calculated by (Rotenone/Antimycin A)/(basal rate). 
MCF-7 cells also showed some variation in the non-mitochondrial oxygen consumption 
rates, varying between 0.17 pMoles/min at 10 nM and 25 pMoles/min at 3 nM 
however this has also been shown to not be significant (p=>0.05). Here the non-
mitochondrial oxygen consumption can be seen to vary between cell lines. In MCF-7 
there is an increase in oxygen consumption and in the MDA-MB-231 cells there is a 
decrease however these changes are not significant. Therefore it can be concluded 
form these results that FK866 does not have an effect of the oxygen consumption rate 
of the mitochondria in both MCF-7 and MDA-MB-231 cell lines. 
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3.2.2 Extracellular acidification rates (ECAR) 
The rate of extracellular acidification (ECAR) reflects the rate of glycolysis. This 
pathway generates ATP and changes to the ECAR generally indicate changes in ATP 
synthesis rates which occur in response to the changes in ATP consumption. The ECAR 
is stimulated by glucose and oligomycin before the mitochondrial respiration is 
inhibited by rotenone and Antimycin A which gives the spare glycolytic activity. The 
non-glycolytic effect is measured after 2-deoxy-glucose (2-DG) is added to inhibit 
glycolysis. As ECAR is the measurement of acidification, it is measured in milli-pH units 
per minute (mpH/min). The extracellular acidification was measured in the MDA-MB-
231 cell line with varying concentrations of FK866. This would indicate if inhibiting 
Nampt in these cells has any effect on glycolytic activity. 
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Figure 3.3: The rate of extracellular acidification of MDA-MB-231 (a) and MCF-7 (b) cell line after varying 
concentrations of FK866 after 24 hours (number of individual experiments = 3; number of repeats per 
experiment = 2). This bar chart indicates basal ECAR in both cell lines, is glucose stimulated ECAR, shows 
oligomycin stimulation, is spare glycolytic ECAR and finally indicates non-glycolytic ECAR. 
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MDA-MB-231 (Figure 3.3 a) and MCF-7 (Figure 3.3 b) cells were treated with FK866 at 
concentrations of 1 to 100 nM for 24 hours and ECAR was measured. The basal ECAR in 
both cell lines showed no significant change over the varying concentrations with 
measurements varying from 1.6mpH/min at 100 nM and 3.97 mpH/ min for 30 nM in 
MDA-MB-231 and 5.52 mpH/min for the 100 nM to 8 mpH/min for the control in MCF-
7 cells (p=>0.05). These results indicate that there is some increase in the basal rates 
with increasing concentration of FK866. Glucose stimulated ECAR seemed to have 
similar results in both cell lines with an increase from 9.52 mpH/min for the control to 
13.48 mpH/min for 100 nM in the MDA-MB-231 cell lines. The MCF-7 cells showed an 
increase from 6.18 mpH/min for the control to 12.4 mpH/min for 1 nM and 9 mpH/min 
for 10 nM however this then drops to 4.6 mpH/min for the 100 nM. Neither of these 
results were significant (p=>0.05). When stimulating with glucose it can be seen to 
have different responses between the cell lines. MCF-7 shows a result that would be 
expected with a gradual decrease over the higher concentrations of FK866 however 
the MDA-MB-231 cell line shows a gradual increase over the increase in concentrations. 
This could be due to the difference between cell lines. Oligomycin inhibits ATP 
synthase by blocking the proton channel which is necessary for oxidative 
phosphorylation of ADP to ATP. The stimulation of basal ECAR with oligomycin in MDA-
MB-231 shows a similar response as the stimulation of glucose where the control rate 
was 18.79 mpH/min increasing to 28.2 mpH/min for 30 nM. This indicates that there is 
an effect on the glycolytic activity with FK866 (p=>0.05). The MCF-7 cells shows an 
increase in the ECAR rate with oligomycin stimulation for 6.2 mpH/min for control to 
12.4 mpH/min for 1 nM, dropping to 4.6 mpH/min for 100 nM which is significant 
(p=<0.05) it also shows that as the concentrations of FK866 increase there is a slight 
decrease in the ECAR rates. This again indicates that the inhibition of Nampt needs to 
be greater to have a lowering effect on stimulation of glycolysis. Spare glycolytic 
capacity was calculated with the (oligomycin-2-DG)/(glucose-2-DG). It is expected that 
FK866 would show a decrease in glycolytic activity which is what is seen in the MCF-7 
cells. It can be seen from the results that there is little change between treatments in 
the MDA-MB-231 cells, varying from 1.93 mpH/min in the control to 2.26 mpH/min at 
30 nM. MCF-7 cells shows a difference between the spare glycolytic capacity with rates 
varying from 1.7 mpH/min for 1 nM to 5.2 mpH/min for 100 nM however there does 
38 
 
not seem to be any significance in either of these results (p=>0.05). The non-glycolytic 
ECAR shows some change over concentrations. In MDA-MB-231 cells there seems to 
be an increase over the varying concentrations of FK866 with 0.26 mpH/min for the 
control to 0.62 mpH/min for 1 nM (p=>0.05). This indicates that FK866 also has some 
effect on the ATP production after inhibiting glycolysis. By having an effect on the ATP 
production, it therefore would have an effect on not only the metabolism in cells but 
also cellular processes such as cell division The variation shows between treatments 
with 0.17 mpH/min for 3 nM to 1.57 mpH/min of the control in MCF-7 cells (p=>0.05). 
Although these results do not reach significance, it might suggest that FK866 has some 
effect on glycolysis. It can be seen that although the stimulation of ECAR by glucose 
and stimulation of basal ECAR with oligomycin show some increase in mpH/min 
therefore indicating there is an increase in glycolytic activity when treating with lower 
concentrations of FK866; the higher concentration of 100 nM shows some decrease 
meaning inhibition of Nampt and therefore the reduction of NAD+ has an effect on 
glycolysis but this is only with higher concentration of inhibitor it could indicate high 
levels of inhibition are necessary for the effect. 
3.2.3 NAD+/NADH 
NAD+ is involved in glycolysis, where it is reduced to NADH, and FK866 has been 
involved in inhibiting Nampt which recycles NAD+. Therefore the NAD+:NADH ratio was 
measured to see what the effect would be on the ratio after treatment of FK866 after 
24 hours. 
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Figure 3.4: The NAD
+
:NADH ratio measured using NAD
+
 and NADH cycling assay to see whether the ratio 
alters with the varying treatments of FK866 in MDA-MB-231 and MCF-7 cells (number of experiments = 
3; number of repeats per experiment = 5). 
The NAD+:NADH ratio (Figure 3.4) was measured first by the NAD+ and NADH levels in 
each cell line 24 hours after treating with varying concentrations of FK866. Both cell 
lines in general show a decrease in NAD+:NADH ratio which is to be expected due to 
the reduction in NAD+ levels whilst treating with FK866. With MDA-MB-231 cells there 
is some decrease in the NAD+:NADH ratio from the control at 2.1 to 1.6 for the 100 nM 
treatment where this is statistically significant (p=<0.05). However for the MCF-7 cell 
line the NAD+:NADH ratio seems to stay relatively the same varying from 2.4 for the 
control to 3.5 for 1 nM back to about 2.7 for the 100 nM concentration, and these 
results are not significant (p=>0.05). 
From these results, it can be deduced that there is no effect on oxygen consumption 
rate in the mitochondria in MDA-MB-231 and MCF-7 cells with varying treatments of 
FK866
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FK866 after 24 hours. It is also seen there is a change in glycolytic activity in both cell 
lines, where both seem to have an increase in glucose stimulated ECAR and stimulation 
by oligomycin, however there was some change in the MCF-7 cells. There is a 
difference between the non-glycolytic. It was increased in the MDA-MB-231 cell line 
when treated with FK866 however; the MCF-7 doesn’t seem show any change. The 
NAD+:NADH ratio also does not seem to alter with varying concentrations in the MCF-7 
cells whereas with the MDA-MB-231 cells this does decrease. The non-glycolytic ECAR 
shows only an effect on the MDA-MB-231 cells, which could be a connection to the 
NAD+:NADH ratio. Therefore from these results we can see that by decreasing NAD+ via 
inhibiting Nampt with FK866  there is an effect on both cells when stimulating 
glycolysis either with glucose or oligomycin however this is only the case with higher 
concentrations of FK866 which means that glycolysis is not sensitive to low levels of 
inhibition of NAD+ over 24 hours. 
 
3.2.4 The Mechanisms of NAD+ consumption whilst treating with FK866 
The effects of FK866 has been well documented (Hasmann and Schemainda 2003; 
Holen et al.,2008 Tolstikov et al., 2014), however this is not the case for NAD+ 
dependent enzymes when inhibiting Nampt, therefore this was investigated using the 
MDA-MB-231 cell line. In this study the cells were treated with either FK866, an 
inhibitor of NAD+ consuming enzymes or a combination of the FK866 and NAD+ 
inhibitor. NAD+ levels were then measured every 2 hours between 4 and 8 hours. From 
these results, it will be clear which enzyme is the main consuming enzyme of NAD+ in 
each of this cell line. 
MDA-MB-231 is a triple negative cell line so it is assumed that there would be higher 
concentration of PARP-1. It was hypothesized that PARP-1 would therefore be the 
main consumer of NAD+ within this cell line. 
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4-Amino-1,8-naphthalimide (NPH) 
NPH is a specific PARP-1 inhibitor. MDA-MB-231 cells were treated for an 8 hour 
period with 3 separate treatments, FK866, NPH or a combination of FK866 and NPH. 
NAD+ was then extracted and measured using the NAD+ cyclic assay and was calculated 
in comparison to the control. 
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Figure 3.5: MDA-MB-231 cell line was treated over 8 hours with FK866, NPH, or a combination of both 
FK866 and NPH. The results show the percentage of NAD
+
 compared to 0 hour time point to indicate 
what percentage of the consumption of NAD
+
 can be attributed to PARP-1 whilst inhibiting Nampt. 
(number of experiments = 4; number of repeats per experiment = 5). 
PARP-1 is a major consumer of NAD+. However from Figure 3.5 it can be seen that 
PARP-1 does not seem to play a significant role in consuming NAD+ whilst inhibiting 
Nampt with FK866, which is indicated by the 3.61% decrease at the 8 hour time point 
in NAD+ levels from the combination of the two inhibitors compared to treating with 
FK866 itself. This result does not seem to be significant (p>=0.05) and due to the small 
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value could be due to natural variation within the cells. It was originally suspected that 
PARP-1 was a main consumer of NAD+ however these results indicate that this is in fact 
not the case. However as there is only a 5% difference in NAD+ levels when comparing 
NPH treated cells to the control vehicle cells this could indicate that the results may 
differ with a longer incubation period. Also as NPH is a specific PARP-1 inhibitor it may 
be possible that if treated with PARP inhibitor Olaparib the results may differ as 
Olaparib inhibits PARP-1 and PARP-2 as there is some evidence to suggest that PARP-2 
replaces PARP-1 when PARP-1 is inhibited.  
Sirtinol 
Sirtinol inhibits Sirt1 in mammalian cells. The cells were treated over an 8 hour period 
with 3 separate treatments, FK866, Sirtinol or a combination of both FK866 and Sirtinol. 
The NAD+ was then measured using the NAD+ cyclic assay and then calculated in 
comparison to the control. 
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Figure 3.6: MDA-MB-231 cells were treated with FK866, Sirtinol, or a combination of both FK866 and 
Sirtinol over an 8 hour period. The NAD
+
 levels were then calculated to a percentage of 0 hour time 
point to show the consumption of NAD
+
 with Sirt1 whilst inhibiting Nampt (number of experiments = 4; 
number of repeats per experiment = 5). 
Sirt1 is an NAD+ dependent histone deacetylase (Cui et al., 2015).  The combination of 
FK866 and Sirtinol has shown some change in the NAD+ levels (Figure 3.6) in 
comparison to the FK866 alone which has a value of 53.45% when treated for 8 hours 
(p=<0.05) in comparison to 0 hours whereas the combination of the two treatments 
have a value of 103.8% in comparison to 0 hours (p=>0.05). Sirtinol alone showed a 
drop in NAD+ levels to 69.12% (p=>0.05). It was predicted that PARP-1 would be the 
main consumer of NAD+ in MDA-MB-231 cells however from these results it can be 
seen that Sirt1 seems to consume more NAD+ in this cell line than PARP-1. 
Kuromanin 
Kuromanin is a flavonoid which inhibits CD38 (Kellenberger et al., 2011). The cells were 
treated over an 8 hour period with FK866, Kuromanin or a combination of both. The 
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NAD+ was extracted and measured using NAD+ cyclic assay and was calculated in 
comparison to the control. 
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Figure 3.7: MDA-MB-231 cells were treated over 8 hour period with FK866, Kuromanin, or a 
combination of both treatments before the NAD
+
 levels were measured and calculated to a percentage 
of the 0 hour time point, which shows the consumption of NAD
+
 that can be attributed to CD38 whilst 
inhibiting Nampt (number of experiments = 4; number of repeats per experiment = 5). 
It has never been reported whether MDA-MB-231 expresses CD38 or not, so is unclear 
about what results would occur with this treatment; however the single treatment 
with Kuromanin seems to show very little change in the NAD+ levels dropping to 86% 
which is the same as the natural drop seen in the control samples (p=>0.05) (Figure 
3.7). When combining the treatments the decrease in NAD+ levels were at 43.9% which 
was 9.56% increase in NAD+ levels when treated with FK866 alone (p=>0.05). From the 
single treatment results, it could be assumed that CD38 is not expressed in MDA-MB-
231 cells however from the combination treatments it can be seen that the NAD+ 
levels are increased after 8 hours of treatment and therefore would indicate the 
presence of CD38. The presence or absence of CD38 in MDA-MB-231 cells will need to 
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be verified via PCR as from this experiment it would seem to be inconclusive regarding 
the expression of CD38 in MDA-MB-231 cells.  
 
3.3 Discussion 
This study shows the effect of FK866 on glycolytic mechanisms, as well as which NAD+ 
consuming enzymes are the main contributors to NAD+ consumption when inhibiting 
Nampt. The knowledge from this study could help influence decisions about which 
pathways may be suitable for pharmacological targeting with FK866 as a co-therapy 
agent. NAD+ is a major component in cellular biochemistry. NAD+ is involved in 
glycolysis as well as DNA repair (PARP) and histone deacetylation (sirtuins) (Berger et 
al., 2004). The salvage pathway for the biosynthesis of NAD+ involves Nampt which 
converts NAM into NMN before it is converted to NAD+ using NMNAT (Figure 3.1). 
Nampt is targeted by FK866 which binds to the NAM binding site. It has been 
suggested that inhibition of this and limiting NAD+ availability, can inhibit major 
processes in cancer cells such as DNA repair and glycolysis, and induce the cells into an 
autophagic style cell death (Billington et al., 2008). Cancer cells have high metabolism 
and high levels of glycolysis (Raghaven et al., 2016). The Warburg effect is the 
metabolic change observed in cancer cells from oxidative phosphorylation to glycolysis 
as the primary source of cellular energy (Warburg 1956). NAD+ and NADH play a major 
role as co-enzymes in accepting and donating hydride ions in the glycolysis pathway, 
the respiratory chain and the redistribution of electron equivalents generated from 
these catabolic pathways in the de novo biosynthesis of macromolecules (Houtkooper 
et al., 2010). Generally in a healthy cell, NADH, which is produced from the 
glyceraldehyde-3-phosphate dehydrogenase reaction, can be reoxidised to NAD+ by 
the lactate dehydrogenase reaction, the citric acid cycle or the mitochondrial 
respiratory chain. The NAD(H)-reoxidation occurs in conjunction with the rate at which 
uncoupled respiration takes place, for instance under conditions of high uncoupling 
protein (Houtkooper et al., 2010). During this study it was theorised that FK866 would 
have an inhibitory effect on glycolysis due to its effect on Nampt and NAD+ recycling. 
This would be because Nampt is a rate limiting enzyme involved in NAD+ biosynthesis, 
46 
 
so by inhibiting this enzyme the biosynthesis rate of NAD+ would be decreased. The 
glycolytic pathway would therefore be slowed and the cell metabolism would be 
affected. The SEAHORSE XF24 measures oxygen consumption and extracellular 
acidification which can be used to calculate the metabolic rate of cells and was 
therefore used to identify if FK866 played a part in disrupting this process. 
Both cell lines were treated for 24 hours with varying treatments of FK866 and then 
were run on a XF24 seahorse to measure the OCR and ECAR, as well as running NAD+ 
and NADH cyclic assays to measure NAD+: NADH ratio. Changes to cellular metabolism 
capacity can be a component in causing cellular dysfunction caused by changes in 
oxidative stress (Rovito and Oblong 2013). Nicotinamide has been shown to partially 
protect oxidative phosphorylation however this is not in a dose dependent manner. It 
is also not able to restore to control levels after oxidative damage occurs, which 
suggests protection of glycolysis (Rovito and Oblong 2013). From the OCR results, it 
can be determined that there does not appear to be any change between the control 
and the varying concentrations of FK866 in both MDA-MB-231 and MCF-7 cell lines. 
The FK866 does not appear to have any effect on the oxygen consumption rates which 
is indicative of no effect on oxidative stress. This correlated with Warburg’s hypothesis 
which states that cancer cells develop a defect in the mitochondria that leads to 
impaired aerobic respiration which therefore means that in these cells, FK866 would 
not have an effect on oxidative stress (Vander Heiden et al., 2009). Cells will increase 
glycolysis to meet the energy demand whilst being treated with oligomycin (Nickens et 
al., 2013). This can be seen in all these samples with an increase from the basal line on 
the ECAR. Over varying concentrations, the ECAR results show a general increase in 
glucose stimulated ECAR and stimulation by oligomycin until 100 nM FK866 which 
shows a decrease. This indicates that the lower concentrations of this drug do not 
inhibit NAD+ biosynthesis enough to have any effect on these cells and particularly 
with 1 nM treatment it seems to increase glycolytic activity when stimulated by 
glucose and oligomycin. There is no change in the spare glycolytic capacity and non-
glycolytic ECAR in MDA-MB-231 cells however there is some change in the spare 
glycolytic capacity in the MCF-7 cells. This would indicate that FK866 is still having 
some effect on MCF-7 cells without stimulation to glycolysis and seems to increase the 
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spare glycolytic capacity where which therefore indicates that FK866 has a negative 
effect on the electron transport chain in the mitochondria. The spare glycolytic 
capacity is measured after the interference of the electron transport chain by 
Antimycin A and Rotenone. Therefore FK866 does appear to have some effect on the 
glycolysis in both cell lines; however MDA-MB-231 cells appear to need more 
stimulation from glucose and oligomycin. It does not appear to have any effect on 
oxygen consumption therefore meaning the cells are still respiring as normal over 
increasing concentrations of FK866. 
NAD+ plays an important role in energy production and cellular resistance to stress. 
FK866 mediates NAD+ depletion through competitive inhibition of Nampt, a key 
mitochondrial enzyme involved in the regulation of NAD+ biosynthesis from 
nicotinamide (Hasmann and Schemainda 2003; Muruganandham et al., 2005; Gehrke 
et al., 2014). In the MDA-MB-231 cell line there appears to be a decrease in the 
NAD+:NADH ratio, whereas MCF-7 cells, there is no change. This indicates that in MDA-
MB-231, FK866 does exhibit an effect on the NAD+:NADH ratio levels, which can be 
seen when looking at the results from the PARP, Sirtinol and CD38 inhibition with 
Nampt inhibition. The MCF-7 does not appear to exhibit any alteration in the 
NAD+:NADH ratio; however FK866 does seem to have some effect on the glycolysis. In 
both cell lines FK866 does appear to have some impact on the glycolysis. In both cell 
lines the NAD+ and NADH levels decreased; however the MCF-7 cells appeared to 
decrease at a similar rate keeping the ratio the same between the two for all 
concentrations, whereas the rate of decrease of NAD+ was higher than the rate of 
decrease in NADH, therefore altering the ratio in the MDA-MB-231 cells. Tumour cells 
can produce high levels of NAD+ and NADH which can alter metabolic activities and can 
be linked to mitochondrial dysfunction that inhibits OXPHOS and increase reactive 
oxygen species (ROS). This promotes uncontrolled cell growth can cause further DNA 
damage (Santirdrian et al., 2013). The ratio of lactate and pyruvate is connected with 
the NAD+:NADH ratio within the cells. This means that if the metabolic activity 
increases and the oxygen availability decrease, the result will be increased glycolysis 
rates and therefore an increase in the local lactate production (Wilhelm and Hirrlinger 
2012). 
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PARP, sirtuins and CD38 are all NAD+ consuming enzymes. PARP-1 forms negatively 
charged PAR on the target protein by cleaving NAD+. By inhibiting PARP-1, the 
depletion of NAD+ and ATP can be protected (Bakondi et al., 2004; Erdelyi et al., 2009; 
Canto et al., 2013). PARP-1 is important to DNA damage response which has 
stimulated the development of small molecule PARP inhibitors as potential therapeutic 
agents for cancer. When treating MDA-MB-231 cells with NPH and FK866 together 
there was very little change in NAD+ levels. This shows that in the triple negative cell 
line, which is expected to have high levels of PARP, the NAD+ consumption is not 
significantly affected by the inhibition of PARP-1. This could be due to the fact that 
PARP-1 and PARP-2 have similar uses and when one is inhibited the other replaces its 
use (Steffen et al., 2013). To investigate this it would be advised to repeat using a 
PARP-1 and PARP-2 inhibitor for example Olaparib. 
Sirtuins are a group of NAD+ dependent deacetylases which regulate eukaryotic 
metabolism (Cui et al., 2015), however unlike most deacetylases, Sirt1 uses NAD+ to 
produce NAM and O-acetyl-ADP-ribose when removing acetyl modification on lysine 
residues. From the results, we have seen that Sirtinol has a reversing effect on NAD+ 
levels over an 8 hour period in MDA-MB-231 cells. Sirt1 expression has been seen in 
most human breast cancer samples and its expression has been connected to distant 
metastasis and poor prognosis (Chung et al., 2015). During this study, MDA-MB-231 
showed that there was no change in consumption of NAD+ when treating with both 
FK866 and Sirtinol when compared to the control. This indicates that the main 
consumer of NAD+ when inhibiting Nampt is Sirt1 in MDA-MB-231 cells.  
CD38 is a NAD+ glycohydrolase that produces ADPR and nicotinamide which accounts 
for more than 90% of all NAD+ase activities in humans (Young et al., 2006; Vaisitti et al., 
2011). It is a widely used as a negative prognostic marker by clinicians in chronic 
lymphocytic lymphoma (CLL), as it is expressed on the surface of CLL cells (Vaisitti et al., 
2011). It was unclear as to whether MDA-MB-231 expresses CD38. However when 
combining the Kuromanin and FK866 treatments there was some increase in the NAD+ 
levels when comparing with FK866 alone. This would indicate that either there is some 
CD38 present or that Kuromanin has an effect on another NAD+ consuming enzymes. 
However this cannot be proven without completing PCR analysis. 
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The results from the SEAHORSE have shown that FK866 does not have an effect on 
oxygen consumption in either of the breast cancer cell lines; however it does have an 
effect through the stimulation of glucose and oligomycin which inhibits the ATP 
synthase in glycolysis. This reduces the electron flow through the electron transport 
chain but does not stop the process completely due to a proton leak or mitochondrial 
uncoupling. This therefore, indicates some increase in glycolysis, however there is no 
significant difference. The NAD+:NADH ratio shows a decrease in the MDA-MB-231 cell 
line after varying treatments of FK866 but not in the MCF-7 cells, this ratio decrease 
may be connected to the non-glycolytic activity increase. Inhibition of CD38 did cause 
some attenuation in the MDA-MB-231 cells. Inhibition of PARP-1 caused a slight 
attenuation suggesting that PARP-1 is partially responsible for the NAD+ consumption 
in this cell line as well. Treatment with Sirtinol to inhibit Sirt1 completely reversed the 
FK866-induced NAD+ activity in MDA-MB-231 cells. This suggests that sirtuin activity is 
the major mechanism responsible for NAD+ consumption whilst inhibiting Nampt in 
MDA-MB-231 cells. This data will help identify cells that may be particularly responsive 
to FK866 and helps to identify possible co-therapies for these cells. 
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Chapter 4: Co-treatment of FK866 and 
anti-cancer agents in MDA-MB-231 and 
MCF-7 cells 
4.1 Introduction 
Nampt is a multifunctional protein which has potential immunoregulatory properties. 
Originally it was assumed to be involved in B cell development as a cytokine (Rongvaux 
et al., 2002), however it is now known to be a rate limiting enzyme which is involved in 
the first step of NAD+ biosynthesis. Nampt is over expressed in cancers such as breast, 
colorectal, gastric, lung and prostate, suggesting that it plays a crucial role in the 
tumour physiology (Hufton, 1999; Gehrke et al., 2014; Sociali et al., 2016). Nampt has 
been proven to be present in high concentrations in the cytosol as well as the nucleus; 
therefore the down regulation of Nampt can control tumour growth both in vitro and 
in vivo as well as sensitising cells to DNA damaging agents (Hasmann and Schemainda 
2003). This can lead to a decrease in tumour growth and an induction of apoptosis 
caused by NAD+ depletion which is due to NAD+ being a substrate for PARP and sirtuins. 
Originally FK866 was thought of as a non-competitive inhibitor of Nampt however 
recently it has been seen to directly compete with nicotinamide for the Nampt active 
site which induces apoptosis (Hasmann and Schemainda 2003; Gehrke et al., 2014). As 
FK866 is not cell cycle dependent it is therefore not involved in multi-drug resistance 
(Holen et al., 2008). It reduces intracellular NAD+ which can result in selective deaths in 
solid tumours (Hasmann and Schemainda 2003; Billington et al., 2008; Travelli et al., 
2011; Gehrke et al., 2014). Nampt inhibitors such as FK866 have shown anti-cancer 
activities in pre-clinical models of both solid and hematologic cancers (Galli et al., 2013; 
Sociali et al., 2016). This is seen by the depletion of NAD+ and ATP levels which led to 
tumour growth inhibition (Hasmann and Schemainda 2003; Galli et al., 2013, Sociali et 
al., 2016). FK866 has been shown to cause delayed cell death which demonstrates 
characteristics of autophagy which is brought about by cell nutrient denial (Billington 
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et al., 2008). With a lack of nutrients, the cells must gain energy and amino acids 
through self-digestion (Gozuacik and Kimchi 2007). In cancer cells, where apoptosis is 
unavailable because of the anti-proliferative control, autophagy is thought of as the 
second type of programmed cell death. A decrease in NAD+ levels leads to an energy 
saving response which is expected as NAD+ is important for glycolysis, the Kreb’s cycle 
and lipid-oxidation.  
PARP is a major enzyme involved in DNA repair, as well as being involved in apoptosis, 
which is activated by DNA damage in tumour cells. Damage to DNA which could have 
occurred either directly, such as ionising radiation or mono-functional alkylating agents, 
or indirectly after an enzymatic cut in the DNA strand, can set off an acute cellular 
response as well as the synthesis of poly(ADP-ribose) by PARP. It may be possible that 
autophagy is associated to the background of PARP-induced cell death (Xu et al., 2006) 
which would be due to the reduction of NAD+ levels. Sirtuins are a family of enzymes 
which have progressively been acknowledged to be important to cancer (Moore et al., 
2012), but their involvement in breast cancer genesis and evolution remains to be 
explained. Sirt1 is a NAD+-dependent histone deacetylase (HDAC) that has been linked 
to longevity, gene silencing, control of the cell cycle and energy homeostasis (Landry et 
al., 2000; Borra et al., 2005; Haigis and Guarente 2006; Dai et al., 2007; Byles et al., 
2010). It also has roles in neuro-degeneration and inflammation (Yamamoto et al., 
2007). Sirt1 is also involved with the tumour suppressor protein itself (Motta et al., 
2004; Pruitt et al., 2006; Dai et al., 2007).  
As seen in Chapter 3, over an 8 hour period FK866 has an effect on the NAD+ levels 
within different cell lines. It can also be seen that by inhibiting with a combination of 
NAD+ consuming enzyme inhibitors that this can be reversed. The effect of pre-treating 
MDA-MB-231 and MCF-7 cells with FK866 for 8 hours, reducing the NAD+ levels, before 
treating with a secondary treatment will be investigated in this chapter by assessing 
the cell vitality as well as the NAD+ levels. The secondary treatments include 4-amino-
1,8-npahthalimide (NPH) (a PARP-1 inhibitor), Olaparib (a PARP-1 and 2 inhibitor), 
Sirtinol (a Sirtuin inhibitor) or Temozolomide (a methylating agent). It is hypothesised 
that there will be a synergistic effect when the cells are treated with a co-treatment as 
the NAD+ levels will have been significantly reduced after the 8 hours prior to 
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secondary treatment. Therefore it should be observed which of these treatments 
would be viable for co-therapy with the breast cancer cell lines MDA-MB-231 and 
MCF-7.  
 
4.2 Results 
The cell vitality and NAD+ levels were measured in both cell lines over both 48 and 72 
hour periods to analyse whether pre-treating cells with FK866 for 8 hours before a 
second treatment would have an effect on the cells, as a possible co-therapy. The cell 
vitality was initially measured with treatments only to allow for comparison to the 
treatments with FK866. 
Initially the MDA-MB-231 and MCF-7 cell lines were treated with FK866 alone as and 
the cell vitality was measured after 3 days. It was seen previously that FK866 has an 
effect on NAD+ levels after 8 hours so this experiment aims to show if after 72 hours as 
a single treatment, that the cells are viable or not. 
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Figure 4.1: Cell vitality measured by MTT assay in MDA-MB-231 and MCF-7 cell lines treated with 
varying concentrations of FK866 (number of individual experiments = 4; number of repeats per 
experiment = 2). It can be seen that over these concentrations there is a significant decrease in cell 
vitality in both cell lines. 
As seen in the previous chapter, FK866 decreases the NAD+ levels after 8 hours and 
also has some effect, although not significant, on the glycolytic activity therefore it can 
be assumed that there would be some effect on the cell vitality after the cells were 
treated with varying concentrations of FK866 over 72 hours, as shown in Figure 4.1. 
Both cell lines show a decrease in cell vitality over an increase in concentration of 
FK866. The MDA-MB-231 cells show in initial decrease from 3 nM (66.60% of the 
control) to 300 nM (49.53% of the control) (p=<0.05). The MCF-7 cells show an initial 
decrease from 10 nM (82.08% to 49.65% of control treatment cell vitality) to 100 nM 
FK866. In both cell lines these results are seen to be significant (p=<0.05). 
The cell vitality was measured after 72 hours when treating with individual treatments 
of NPH, Olaparib, Sirtinol and Temozolomide. This will indicate how MCF-7 and MDA-
MB-231 cells will behave with single treatment. 
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Figure 4.2: MDA-MB-231 (a) and MCF-7 (b) were treated with one of four treatments including NPH, 
Temozolomide, Sirtinol or Olaparib for 3 days. The cell vitality was then measured using the MTT assay 
and was calculated as a percentage of the control (number of individual experiments = 3; number of 
repeats per experiment = 2) 
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Before the co-treatment of the cells with FK866 and a secondary treatment could be 
carried out, the cells were treated with only the secondary treatments to analyse any 
effects on the cell vitality. The cells were treated for 72 hours with NPH, Olaparib, 
Sirtinol or Temozolomide before the cell vitality was measured using the MTT assay 
(Figure 4.2). From the results it can be seen that the MDA-MB-231 cells (Figure 4.2a) 
showed very little change in cell vitality when treated with NPH, with the cell vitality 
decreasing to 89.31% when treating with 10 µM (p=>0.05). Conversely the MCF-7 cell 
line (Figure 4.2b) exhibited an apparent increase in cell vitality to 137.43% when 
treated with 30 µM, these results however are not significant (p=>0.05). When treating 
with Olaparib there seems to be a slight dip in the cell vitality at lower concentrations 
of treatment before the vitality increases. The MDA-MB-231 cells show a dip in the cell 
vitality to 86.16% when treated with 1 µM Olaparib increasing to 118.47% when 
treated with 30 µM Olaparib (p=>0.05). The MCF-7 cells show a drop in cell vitality to 
78.79% of the control when treated with 300 nM Olaparib before increasing to 95.62% 
of control when treated with 30 µM Olaparib, again these results are not significant 
(p=>0.05).  Both cell lines, when treated with Sirtinol also show a slight dip in cell 
vitality over lower concentrations before recovering at higher concentrations although 
this seems to be more prominent in the MCF-7 cells as opposed to the MDA-MB-231 
cells. In the MDA-MB-231 cells the dip is seen at 1 µM with a cell vitality of 73.19% of 
the control, with higher concentrations of treatment this increases to 104.96% of the 
control at 30 µM Sirtinol (p=>0.05). In the MCF-7 cell line the dip is also seen at 1 µM 
however the cell vitality drops further than in the MDA-MB-231 cell line showing a 
percentage of 67.44% of the control (p=>0.05).  At the higher concentrations the cell 
vitality increases to 118.27% when treating with 100 µM Sirtinol (p=>0.05). When 
treating with TMZ however the cell lines behave quite differently, where the MDA-MB-
231 cells show a drop in cell vitality the MCF-7 cells show an increase in cell vitality. 
The MDA-MB-231 cells show a drop in the cell vitality to 51.52% of the control when 
treating with 30 µM TMZ however the MCF-7 cells show an increase in cell vitality to 
129.40% of the control when treating with 30 µM TMZ (p=>0.05). These results 
indicate that although with some treatments the cell lines can behave similar the 
treatments can be different depending on the type of cell used. 
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4.2.1 Co-therapy 
MDA-MB-231 and MCF-7 cells were treated with 10 nM FK866 for 8 hours prior to 
treatment with NPH, Olaparib, Sirtinol or TMZ for 48 or 72 hours. After the 48 or 72 
hours has passed the cell vitality and NAD+ levels were measured. As it was seen in 
Chapter 3 the NAD+ levels decrease after 8 hours of treatment with FK866 therefore 
the pre-treatment with the FK866 will reduce NAD+ levels which could add to the 
effect that these treatments may have on both cell vitality and NAD+ levels. 
 
a 
4-Amino-1,8,Naphthalimide 
Cell Vitality NAD+ 
 
48 h 72 h 48 h 72 h 
 
Control 100 100 100 100 
 
100 nM 108.94 63.90 113.74 58.19 
 
300 nM 118.32 73.47 36.41 188.25 
 
1 µM 128.83 82.65 48.36 153.25 
 
3 µM 146.95 92.45 42.79 145.56 
 
10 µM 140.10 102.24 34.46 66.62 
 
30 µM 138.48 80.07 66.81 107.17 
 
100 µM 130.47 82.84 57.61 98.47 
      b 
Olaparib 
Cell Vitality NAD+ 
 
48 h 72 h 48 h 72 h 
 
Control 100 100 100 100 
 
100 nM 105.20 121.55 182.75 102.61 
 
300 nM 115.19 111.55 72.57 93.65 
 
1 µM  118.54 121.38 129.08 96.05 
 
3 µM  138.98 136.87 165.16 66.20 
 
10 µM  141.41 130.61 191.95 78.11 
 
30 µM  131.20 117.44 100.24 79.26 
 
100 µM  124.12 105.56 129.97 80.99 
      c 
Sirtinol 
Cell Vitality NAD+ 
 
48 h 72 h 48 h 72 h 
 
Control 100 100 100 100 
 
100 nM 102.37 110.14 98.88 68.38 
 
300 nM 108.54 113.41 81.95 30.65 
 
1 µM  111.41 123.42 106.56 60.66 
 
3 µM  104.14 157.18 94.90 105.88 
 
10 µM  127.73 158.07 64.85 94.74 
 
30 µM  112.34 128.25 103.75 48.74 
 
100 µM  101.94 115.91 97.00 128.16 
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      d 
Temozolomide 
Cell Vitality NAD+ 
 
48 h 72 h 48 h 72 h 
 
Control 100 100 100 100 
 
100 nM 112.72 98.82 252.85 99.01 
 
300 nM 115.53 115.22 265.35 145.20 
 
1 µM  116.54 123.65 329.02 73.71 
 
3 µM  133.97 161.53 144.73 201.31 
 
10 µM  138.06 165.22 218.96 87.92 
 
30 µM  134.70 174.33 321.52 101.70 
 
100 µM  127.13 169.75 401.08 194.84 
Table 4.1: Cell vitality and NAD
+
 of 48 and 72 hour co-treatments in MDA-MB-231 cells when treated 
with a) NPH, b) Olaparib, c) Sirtinol and d) Temozolomide after 8 hour pre-treatment with 10 µM FK866. 
These were compared to cells without treatment to calculate percentage of control (n=3). 
After 48 hours of treatment the cell vitality was measured using the MTT assay to 
assess whether treating with FK866 for 8 hours prior to treatment would have an 
effect on the cell vitality. Generally with each treatment there is not much change in 
the cell vitality after 48 hours when comparing to the control (Table 4.1). When the 
cells were treated with a secondary treatment of NPH for 48 hours both cell lines seem 
to generally show some increase in cell vitality (Table 4.1 a). MDA-MB-231 cells show 
an increase in cell vitality to 146.95% of the control when treated with 3 µM NPH 
(p=<0.05), this does begin to decrease back towards the control rates with higher 
concentrations with a cell vitality of 130.47% when treating with 100 µM NPH 
(p=>0.05), although not as much as in the MCF-7 cell line (Table 4.2a). When treating 
with the second PARP inhibitor, Olaparib, we get similar results where, over the lower 
concentrations the cell vitality increases but then begins to decrease at the higher 
concentrations in both cell lines (Table 4.1b). When treated with 10 µM Olaparib the 
MDA-MB-231 cells increased cell vitality to 141.41% of the control before decreasing 
to 124.12% when treating with 100 µM Olaparib. When MDA-MB-231 cells were 
treated with the Sirt1 inhibitor, Sirtinol, there seems to be a slight increase in cell 
vitality (p=>0.05) (Table 4.1 c). MDA-MB-231 cells show an increase in cell vitality to 
127.73% of the control when treated with 10µM Sirtinol before decreasing to 101.94% 
when treating with 100 µM Sirtinol however none of these show significance (p=>0.05). 
Finally, Temozolomide shows a similar result to previous treatments after 48 hours 
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where there is some increase in cell vitality although it is not significant (Table 4.1 d). 
The MDA-MB-231 cells show an increase in cell vitality to 138.06% of the control when 
treating with 10 µM before decreasing to 127.13% of the control when treating with 
100 µM (p=>0.05).  
The cell vitality was also measured after 72 hours incubation with NPH, Olaparib, 
Sirtinol or Temozolomide after an 8 hour pre-treatment of 10 nM FK866 (Table 4.1). 
When the cells were treated with NPH it was seen to have some decrease in the cell 
vitality at the lower concentrations however this appears to increase when treating 
with higher concentrations of NPH (Table 4.1 a). MDA-MB-231 cells show a sharp 
decrease to 63.90% when treated with 100 nM NPH which then increases to 
102.24%when treated with 10 µM NPH (p=>0.05). When the MDA-MB-231 cell line 
was treated with varying concentrations of Olaparib (Table 4.1 b) it showed an 
increase to 136.87% when treated with 3 µM decreasing to 105.56% when treating 
with 100 µM (p=>0.05). The MDA-MB-231 shows an increase in cell vitality over 
increasing concentrations of Sirtinol (Table 4.1 c) to 158.07% of the control when 
treating with 10 µM (p=>0.05). When treating with Temozolomide there seems to be 
an increase in the cell vitality in the MDA-MB-231 cells (Table 4.1 d). This is seen with 
an increase in cell vitality to 174.33% when treating with 30 µM Temozolomide 
(p=<0.05).  
The NAD+ levels were then measured in samples taken after 48 and 72 hours of 
treatment (Table 4.1). When the cells were treated with NPH after 48 hours there is a 
decrease in NAD+ to 34.46% when treating with 10 µM FK866 (p=<0.05). This could be 
due to MDA-MB-231 cells being a triple negative cell line so therefore more dependent 
of PARP-1. During the Olaparib treatments it was seen that the there was a general 
increase in NAD+ levels after 48 hours (Table 4.1 b). The results show an increase in 
MDA-MB-231 cells to 191.95% NAD+ when compared to the control whilst treating 
with 30 µM Olaparib (p=>0.05). It seems that this is the opposite result that was seen 
in the cells treated with NPH; this could be due to the inhibition of PARP-2 as well as 
PARP-1. When cells were treated with Sirtinol it was seen that MDA-MB-231 cells 
showed no real change in NAD+ concentration when compared to the control (Table 
4.1 c). In MDA-MB-231 the concentration varied between 64.85% of control when 
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treating with 3 µM and 106.56% of control when treated with 1 µM Sirtinol although 
these are not significant when comparing with the control (p=>0.05). Temozolomide is 
a DNA methylating agent which is not known to have any effect of NAD+ levels. From 
the results of the 48 hour treatment shows a large increase in NAD+ levels (Table 4.1 d). 
The MDA-MB-231 cells show an increase to 401.08% NAD+ when compared to the 
control when treated with 100 µM Temozolomide (p=>0.05).   
When the NAD+ levels were measured after 72 hours with NPH (Table 4.1a), the MDA-
MB-231 cells shows some increase at lower concentrations raising to 188.25% when 
treating with 300 nM before decrease back to 98.47% of the control when treating 
with 100 µM NPH (p=>0.05). When treated with Olaparib the cells showed a general 
decrease in NAD+ levels with a decrease to 66.20% when treated with 3 µM Olaparib 
(p=>0.05) (Table 4.1 b). When the cells were treated with Sirtinol they showed an 
initial decrease during the lower concentrations of Sirtinol, dropping to 30.65% when 
treated with 300 nM however this increases again to 128.16% when treated with 100 
µM Sirtinol (p=>0.05). After the cell lines were treated with Temozolomide the NAD+ 
levels were varying however there is a general increase in the NAD+ levels (Table 4.1 d). 
MDA-MB-231 cells where they generally increase to 194.84% when treating with 100 
µM Temozolomide (p=>0.05). When comparing these results to the 72 hour cell vitality 
it can be seen that in general with a change in the NAD+ levels correlate with the 
changes in cell vitality. 
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a 
4-Amino-1,8,Naphthalimide 
Cell Vitality NAD+ 
 
2 Day 3 Day 2 Day 3 Day 
 
Control 100 100 100 100 
 
100 nM 101.95 86.23 145.49 82.03 
 
300 nM 110.90 86.47 104.46 74.84 
 
1 µM  117.72 80.43 90.74 61.20 
 
3 µM  138.09 75.72 103.10 70.16 
 
10 µM  142.64 81.40 123.01 64.07 
 
30 µM  117.93 81.40 137.28 64.88 
 
100 µM  110.25 95.65 223.87 78.72 
      b 
Olaparib 
Cell Vitality NAD+ 
 
2 Day 3 Day 2 Day 3 Day 
 
Control 100 100 100 100 
 
100 nM 105.62 100.21 105.78 94.34 
 
300 nM 109.66 117.25 68.66 108.08 
 
1 µM  114.12 111.29 90.01 74.26 
 
3 µM  130.13 111.09 94.51 69.39 
 
10 µM  131.66 106.37 36.28 54.12 
 
30 µM  119.44 105.13 48.44 79.62 
 
100 µM  119.38 91.58 23.66 32.07 
      c 
Sirtinol 
Cell Vitality NAD+ 
 
2 Day 3 Day 2 Day 3 Day 
 
Control 100 100 100 100 
 
100 nM 101.29 142.26 59.90 64.40 
 
300 nM 110.97 101.18 53.03 44.94 
 
1 µM  105.39 95.12 72.38 49.19 
 
3 µM  123.47 102.36 61.03 65.39 
 
10 µM  126.34 97.47 55.40 84.02 
 
30 µM  128.05 101.68 50.61 59.68 
 
100 µM  114.89 113.30 103.61 58.44 
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      d 
Temozolomide 
Cell Vitality NAD+ 
 
2 Day 3 Day 2 Day 3 Day 
 
Control 100 100 100 100 
 
100 nM 103.58 105.82 118.68 170.70 
 
300 nM 108.46 101.19 82.70 102.02 
 
1 µM  110.94 103.43 109.16 115.22 
 
3 µM  130.13 108.81 98.18 207.35 
 
10 µM  132.60 102.54 85.76 119.28 
 
30 µM  127.92 103.88 65.44 248.71 
 
100 µM  126.03 134.51 60.99 130.33 
Table 4.2: MCF-7 cells were pre-treated for 8 hours with 10 nM FK866 before being treated with either a) 
NPH; b) Olaparib, c) Sirtinol or d) Temozolomide for 48 or 72 hours. The cell vitality and NAD
+
 levels 
were measured and calculated as a percent of the control treatment (n=3). 
The MCF-7 cells were treated in the same method as the MDA-MB-231 cells with the 
data shown in Table 4.2. After 48 hours the cell vitality and NAD+ levels were measure. 
When treated with NPH (Table 4.2 a), the cell vitality increases to 142.64% when 
treating with 10 µM NPH, however this decreases again to 110.25% when treating with 
100 µM NPH (p=>0.05). When treated with the Olaparib (Table 4.2 b) the cells showed 
a general increase in cell vitality with an increase to 131.66% when treating with 10 
µM Olaparib which decreased to 119.37% when treating with 100 µM cell vitality 
(p=>0.05). The increase and decrease in cell vitality with the MCF-7 is not as high as the 
MDA-MB-231 which could be due to the differences in cell line. Both the NPH and 
Olaparib treatments show similar results in both cell lines although the Olaparib does 
not show quite as high a rise in cell vitality, this could be due to NPH being a PARP-1 
inhibitor and Olaparib being a PARP-1 and 2 inhibitor. When these cells were treated 
with Sirtinol (Table 4.2 c) for 48 hours there was an increase to 128.05% with a 
concentration of 30 µM (p=>0.05) which is a similar pattern that is seen in the MDA-
MB-231. The MCF-7 cells show a similar pattern to the MDA-MB-231 cell line when 
treating with Temozolomide (Table 4.2 d) with an increase to 132.60% when treating 
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with 10 µM Temozolomide, before decreasing to 126.03% when treating with 100 µM 
Temozolomide (p=>0.05). These increases in cell vitality, although not significant, could 
indicate an increase in cell proliferation. 
When measuring the NAD+ levels over 48 hours MCF-7 cell line was treated with NPH it 
showed an increase in NAD+ levels to 223.87% when treating with 100 µM NPH 
(p=>0.05). The increase in cell vitality in MCF-7 cells corresponds to the cells having 
more available NAD+ however the MDA-MB-231 cells also show an increase in cell 
vitality with a decrease in NAD+ although this could be due to the cells not responding 
to the decrease in NAD+ levels and would possibly need a longer period of time with 
the treatment to see an effect. The MCF-7 cells show a decrease to 23.66% NAD+ when 
comparing to the control whilst treating with 100 µM Olaparib (p=>0.05). The MCF-7 
cells show a decrease in NAD+ levels at lower concentrations of Sirtinol where there is 
a decrease in the NAD+ levels to 50.61% of the control when treating with 30 µM 
Sirtinol however at the highest concentration it increases again to 103.61% of the 
control (p=>0.05). When the cells were treated with Temozolomide the NAD+ levels 
fluctuated between 60.99% when treated with 100 µM Temozolomide and 118.68% 
when treating with 1 µM Temozolomide in MCF-7 cells (p=>0.05). When comparing the 
cell vitality results with the NAD+ results when cells have been treated for 48 hours it 
indicates that in some cases, for example the NPH in MCF-7 cells there was a 
correlation between increase in NAD+ and an increase in cell vitality which was also 
seen in the MDA-MB-231 cells when treated with Temozolomide. However in some 
cases such as the Sirtinol treatment in MCF-7 cells where the NAD+ levels were 
decreased, the cell vitality was still showing some increase. This could be due to a 
delayed response between lowering of the NAD+ levels and its effect on cell vitality.  
The cells were also treated for 72 hours to see if a longer exposure to the treatment 
would have a greater effect on the cells. The MCF-7 cell line shows a decrease in cell 
vitality to 75.72% of the control when treating with 3 nM NPH (p=>0.05). When 
treating with Olaparib the MCF-7 cells do not show a significant change in the cell 
vitality with an increase to 117.25% when treating with 3 µM Olaparib and a decrease 
to 91.58% when treating with 100 µM Olaparib (p=>0.05). This behaviour is different 
to the inhibition with NPH which could be due to the inhibition of both PARP-1 and 
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PARP-2. The MCF-7 cells however show very little change in the cell vitality when 
treated with Sirtinol except when treating with the lowest concentration which shows 
an increase to 142.26% and begins to show an increase again when treating with 100 
µM with an increase to 113.30% of cell vitality (p=>0.05). This difference in cell lines 
shows similar results as seen in the 48 hour treatment however it seems that the cell 
vitality has increased with the increased treatment time therefore this treatment 
appears more effective than the 48 hours treatment, particularly in MCF-7 cells. The 
MCF-7 cells only appear to show an increase in cell vitality when treating with the 
highest concentration of Temozolomide which has an increase to 134.51% of the 
control (p=>0.05). The cell vitality in both cell lines show similar patterns to the 48 
hour treatment, but depending on the exact treatment, there are some benefits to the 
increased treatment time, particularly when treating with lower concentrations of NPH. 
NAD+ levels were also measured after treatment for 72 hours to determine if there 
was any effect on the NAD+ levels in comparison to the control. NPH has been shown 
to have decreased levels of NAD+ in the MCF-7 cells whereas the MDA-MB-231 cells do 
not exhibit a significant change in NAD+ levels. The MCF-7 cells show a decrease in 
NAD+ levels decreasing to 64.88% when treated with 30 µM NPH (p=>0.05).  However 
when treating with Olaparib, the MCF-7 cells show a decrease to 32.07% when treated 
with 100 µM Olaparib however when treating with 300 nM Olaparib there was an 
increase in the NAD+ levels to 108.08% of the control (p=>0.05). When the cells were 
treated with Sirtinol there was a general decrease in cellular NAD+ levels with a 
decrease to 58.44% when treated with 100 µM (p=>0.05). There was a general 
increase in NAD+ levels to 248.71% when the cells were treated with 30 µM 
Temozolomide (p=>0.05). The MCF-7 cells show a higher increase in NAD+ levels than 
when treated with Temozolomide than the MDA-MB-231 cell line. 
From these results it seems to show that there is a general increase in cell vitality 
which could be due to the increase in cell proliferation when cells are pre-treated with 
10 nM FK866. It was hypothesised that the NAD+ results would correlate with these 
results which are seen in both 48 and 72 hour treatments. 
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4.3 Discussion 
Tumour cells show an increase in glycolysis and a high concentration of NAD+, 
therefore treatments are being developed to target the recycling enzymes. One of 
these treatments is FK866 which targets Nampt, an NAD+ recycling enzyme. It was 
hypothesised that when treating breast cancer cells with FK866 8 hours prior to a 
secondary treatment of with NPH, Olaparib, Sirtinol or Temozolomide for 48 or 72 
hours, there would be a synergistic effect by reducing cell vitality and NAD+ levels. This 
was investigated by measuring the cell vitality using the MTT assay and the NAD+ levels 
using the NAD+ cycling assay. 
FK866 inhibits Nampt therefore decreasing the NAD+ levels which would illicit some 
effect on glycolysis (see Chapter 3). This would therefore have an effect on cell 
proliferation. It has been shown in various cell lines that there is an effect on cell 
vitality when treated with FK866 and it has shown that this is the case with both MCF-7 
and MDA-MB-231 cell lines as well. It was seen in Chapter 3 that there is an inhibitory 
effect on NAD+ levels after 8 hours of treatment by approximately 50%. PARP-1 and 
PARP-2 uses NAD+ as building blocks for repair of DNA so therefore treatment with 
Olaparib or NPH would block this process. The MCF-7 cells when treated for 48 hours 
generally show an increase in cell vitality and NAD+ levels but when treating for 72 
hours the vitality and NAD+ decreased showing that with a longer treatment there is an 
effect when pre-treating with FK866 for 8 hours prior to treatment. However when the 
MCF-7 cells were treated with Olaparib the cell vitality increased although there was 
still a decrease in the NAD+ levels. The MDA-MB-231 shows an increase in cell vitality 
but a decrease in NAD+ levels when treated with 48 hours with NPH however when 
treated for 72 hours it shows an initial decrease before restoring the cell vitality 
whereas the NAD+ shows an initial increase before returning to control levels. When 
treated with Olaparib the cell vitality in the MDA-MB-231 cells were increased, the 
NAD+ levels were increased over 48 hours however after 72 hours the NAD+ levels 
began to decrease. Both treatments seem to have an effect on the cell lines however it 
seems that NPH has more of an effect on the cell vitality although at higher 
concentrations of the treatments there is not a significant difference between cell 
vitality results. This is due to both NPH and Olaparib being PARP inhibitors however 
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NPH only inhibits PARP-1 as opposed to Olaparib which inhibits both PARP-1 and PARP-
2. As there seems to be a decrease in NAD+ when the cells were treated with Olaparib 
but not when treated with NPH this could be due to the inhibition of both PARP-1 and 
PARP-2. Interestingly, studies have shown that increasing concentrations of FK866 with 
a set concentration of Olaparib does seem to show some sensitivity (Bajrami et al., 
2012), however the study continued with media and drug being replaced every 72 
hours for 15 days whereas this study was only conducted for 48-72 hours. 
Sirtinol is a Sirt1 inhibitor. Sirtuins are a major NAD+ utilising enzyme, as seen in 
Chapter 3. They are a family of deacetylases which reverse the acetyl modifications of 
lysine residues on histones using NAD+, producing nicotinamide which is recycled by 
Nampt to form NAD+. From the cell vitality results, there is an increase in the vitality of 
both cell lines although the MCF-7 cells do begin to decrease with higher 
concentrations. The NAD+ levels show a general decrease in both cell lines for both 
time points although the MCF-7 cells also show a recovery in NAD+ levels. There is a 
significant association between the expression of Sirt1 and distant metastasis as well 
as poor prognosis in breast cancer cells (Hiraike et al., 2011; Yuan et al., 2013). It can 
also promote cell survival through the p53 pathway. Oncogenic signalling of estrogen 
receptor α requires Sirt1 (Yuan et al., 2013), which could explain the lack of effect on 
the cell vitality in MDA-MB-231 cells which could be due to MDA-MB-231 cells being 
triple negative as they have no estrogen receptor α. 
Temozolomide is a DNA methylating agent. A methylating agent binds to the DNA, and 
in the case of Temozolomide it binds primarily to guanine, which results in single-
stranded DNA breaks, growth arrest and apoptosis (Horton et al., 2009). As it is able to 
pass the blood brain barrier it is mainly used for malignant glioma tumours. In the 
MDA-MB-231 cell line the treatment showed a general increase in cell vitality when 
treatment over 48 and 72 hours when the cells were pre-treated with FK866. There 
does seem to be an increase in the NAD+ levels however Temozolomide has not been 
shown to have any effect on NAD+ utilising or synthesising enzymes. This is a similar to 
the result seen in MCF-7. The change in NAD+ levels could possibly be due to the single 
strand breaks caused by Temozolomide and therefore inducing a DNA repair response 
from PARP although this has not been proven. 
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From all the results presented in this study, MCF-7 cells show an increase in cell vitality 
with all treatments apart from when treated with NPH where there was a decrease in 
the cell vitality. The MDA-MB-231 shows an increase in cell vitality or very little change 
from the control with all treatments investigated in this study. Although there seems 
to be an adverse effect on the cell vitality the NAD+ results seem to show some 
decrease in NAD+ levels. This could indicate that a decrease in NAD+ and the inhibition 
of Nampt has a protective quality to the cells. It has been reported in another study 
that when inhibiting Nampt in mice the MDA-MB-231 cells appear to metastasise 
when treated with PARP inhibitors (Santidrian et al., 2013). This is another indication 
that Nampt inhibition and therefore the decrease in NAD+ levels and the increase in 
cell vitality could result in metastatic growth. This contradicts the hypothesis however 
from the NAD+ levels it can be seen that even with the inhibition of Nampt at the 
beginning of the incubation and then treating with NAD+ utilising enzyme inhibitors, 
the NAD+ levels do increase which could lead to an increase in glycolytic activity of the 
cells. Potentially a follow on from this experiment would be to pre-treat with the NAD+ 
utilising enzyme inhibitors before treating with FK866 similar to that of Bajrami et al., 
2012; which did indicate MDA-MB-231 cells had some sensitivity to Olaparib after 15 
days when treated with a secondary treatment of FK866. However although there 
does seem to be some effect on these cells when they are pre-treated with FK866 this 
is not significant and therefore from these results it would indicate that FK866 does 
not show a therapeutic benefit after these timepoints however there is the potential 
that there could be some therapeutic benefits when incubating for a longer period of 
time. 
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Chapter 5: Treatment of Cancer Cell 
Spheroid Cultures with FK866 
5.1 Introduction 
Monolayer (2D) cell cultures have been used in cancer research for several decades 
however, they have certain limitations. For example, due to often being grown in a 
non-biological environment such as treated plastics, they develop a flat and stretched 
morphology, and as a result do not experience the same cell to cell interactions as 
seen in in vivo tissues, resulting in them being more susceptible to cytotoxic 
treatments (Nagelkerke et al., 2013; Raghavan et al., 2016). These limitations have 
resulted in a demand for the development of 3D cultures which could provide a more 
viable model as they are able to act more like cells typical to those grown in vivo and 
this could lead to a better understanding of how tumours may respond to therapeutic 
treatments (Dufau  et al., 2012). Cells can adapt to their surroundings and respond to 
signalling regarding cell proliferation, differentiation and function leading to various 
cell morphologies dependent on the environment and other factors (Knight and 
Przyborski 2015). The differences in morphology of monolayer and spheroid cells can 
alter the effect of cellular processes such as apoptosis, proliferation and drug 
sensitivities (Baron et al., 2012; Knight and Przyborski 2015). The differences between 
monolayer and spheroid morphologies also extend to growth patterns, protein 
expression and the relationship with the extracellular matrix (Kim, 2005; Baron et al., 
2012). With the development of spheroid culture, the requirement to use time 
consuming and expensive in vivo studies is reduced. This is because spheroid cultures 
show favourable similarities to in vivo tissues, such as the expression of antigens, pH 
and oxygen gradients within the microenvironment, as well as the rate at which 
growth factors are produced and the distribution of the proliferating cells within the 
spheroid (Dufau et al., 2012; Kim 2005; Baron et al., 2012). 
Investigations into the use of breast cancer cells to produce 3D cell cultures began 35 
years ago (reviewed in Nelson and Bissell 2005). The early investigations into culturing 
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breast cancer spheroids showed that although they should have been able to generate 
relevant physiological behaviours in response to differentiating signals, attempts to 
culture rodent mammary glands failed in the ability to maintain the cells that could 
form acini and produce milk in response to the lactogenic hormone (Nelson and Bissell 
2005).Gene expression in 3D cell culture can produce clinical expression profiles better 
than those generated in 2D cultures. 3D culture can therefore provide an improved 
method for assessing therapeutic methods as well as improving the clinical efficacy 
(Raghavan et al., 2016). Due to this it is now becoming more common to use 3D 
cultures to develop new anti-cancer therapies which should therefore improve pre-
animal and pre-clinical studies for selection of treatment candidates (Kunz-Schughart 
et al., 2004; Hirschaeuser et al., 2010). 3D cultures from human cell lines such as 
breast and ovarian cancers, have been seen to have uses in studies regarding the 
regulation of physiology and therapeutic issues (Rodriguez-Enriquez et al., 2008).This 
makes the study of 3D culture important to understanding cell to cell and cell to matrix 
interactions(Shield et al., 2009). 
Nampt mediated NAD+ biosynthesis in cancer cell lines plays an important role in many 
physiological processes such as metabolism, energy generation, apoptosis, DNA repair 
and inflammation. Nampt activity can be over-expressed in several types of tumour 
including breast cancers. The Nampt inhibitor, FK866 has been the subject of extensive 
studies due to its potential importance in the control of tumours through its inhibition 
of Nampt. The FK866 molecule competitively inhibits Nampt by binding to the 
nicotinamide binding pocket and is specific to Nampt. FK866 also exhibits anti-tumour 
activity in tumour cells (Socialli et al., 2016). 
PARP is a highly conserved enzyme which assists in the repair of DNA. Olaparib is an 
inhibitor of both PARP-1 and PARP-2. When inhibiting PARP-1 and 2 with Olaparib it 
can result in single strand DNA breaks which are of no consequence to normal cells as 
they can efficiently repair this type of DNA damage (Shaw, Hall 2013). However, when 
cells have deficiencies in homologous repair, then single strand annealing would be the 
only mechanism for repairing DNA. By inhibiting PARP, it is unable to assist in 
annealing the single strand breaks which would result in double strand breaks which 
cannot be repaired in cells with BRCA mutations. This can ultimately lead to apoptosis 
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or senescence (Iglehart, Silver 2009; Helleday 2011). This results in cells with the BRCA 
mutation have a higher sensitivity to PARP inhibitors. 
FK866 has only been studied using monolayer and suspension cell cultures, it is 
unknown if its effect on NAD+ levels and cell viability will be the same in 3D cell 
models. NAD+ levels and cell viability were measured in 3D cell cultures treated with 
FK866 and Olaparib and the results were compared to cells grown in monolayer 
cultures. It is hypothesised that cells grown in monolayer culture will be more 
susceptible to treatments of FK866 and Olaparib than 3D cultures due to the lack of 
cell to cell interactions that are present in monolayers. 
 
5.2 Results 
Due to the physiological differences between monolayer and spheroids it has been 
suggested that monolayers are not entirely valid for testing the effect of drugs 
(Hirshchhaeuser et al., 2010). So far all research into FK866 has been carried out in 
monolayer cultures. Therefore in this chapter the effect of FK866 and Olaparib on cell 
viability and NAD+ levels were compared between spheroid and monolayer cultures of 
breast cancer cells. 
Firstly it was important to investigate how the spheroids would be grown. A recent 
publication by Nagelkerke et al., 2013 tested various methods for forming spheroids 
and from their results it was indicated that growing the cells in a v-bottom plate that 
has be pre-treated with poly-HEMA was the best method for spheroid growth. The 
cells were added to the plates and centrifuged for 5 minutes at 800 rpm before being 
left in an incubator for 24 hours for the spheroids to form. This method was therefore 
used in this study. 
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Figure 5.1: Images of a) MCF-7 cells grown in spheroid and b) MDA-MB-231 cells grown in spheroid 
The MCF-7 cells form tight spheroid cultures within 24 hours with no assistance of a 
matrix, which would normally help the cells adhere to one another as well as assisting 
in proliferation and differentiation (Figure 5.1 a). However the MDA-MB-231 cells did 
not form spheroids at all when following this protocol so ECM gel (Sigma Aldrich) was 
used as a matrix to assist with the formation. These cells were also incubated on a 
rotating plate to help the spheroids form. These spheroids formed (Figure 5.1 b) 
however they are loosely formed when compared to the MCF-7 cells. These results 
confirmed the method of spheroid preparation, and allowed assays to be run with 
these cells. To measure the NAD+ levels in the spheroids, the calculations needed to 
take a different approach, therefore the volume of spheroid vs viability was compared 
to determine if there was any correlation between spheroid volume and number of 
viable cells, which would then indicate whether the volume of spheroid could be used 
to calculate NAD+ levels. 
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Figure 5.2: The correlation between the viability of cells and the volume of the spheroid. This indicates 
that as the viability decreases the volume increases although this is not significant (p=>0.05). (number of 
individual experiments = 3; number of repeated per experiment = 5) 
The graph (Figure 5.2) indicates that as the viability of the cells decrease the volume of 
the spheroid increases. However this could be due to the fact that as the viability 
decreases the spheroids appear to be looser. After seeing that there is in fact some 
connection with the volume of the spheroid and the cell viability, the NAD+ levels could 
be calculated using the volume of spheroid as opposed to cell number. 
5.2.1 Cell Viability 
 Cell viability was measured in both MCF-7 and MDA-MB-231 cell lines in monolayer 
treated with FK866. Due to MTT being unable to penetrate spheroids, the APH assay 
was used to measure cell viability as this method has been used in other studies to 
measure cell viability. The APH assay is based on the quantification of cytosolic acid 
phosphatase activity which determines cell viability in both monolayer and spheroid 
cultures. This works when the intracellular acid phosphatase in viable cells hydrolyses 
p-nitrophenyl phosphate to p-nitrophenol which gives a colour change dependent on 
viable cells. 
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Figure 5.3:MDA-MB-231 and MCF-7 cells were treated with varying concentrations of FK866 from 1 nM 
to 300 nM over 72 hours before the cell viability was measured using the APH assay. A) show the results 
of these cells grown under monolayer (number of individual experiments = 3; number of repeats per 
experiment = 2), b) shows the results of these cells grown in spheroid cultures (number of individual 
experiments = 4; number of repeats per experiment = 5) 
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The APH assay was used to measure the cell viability in MDA-MB-231 and MCF-7 cell 
lines grown in monolayer cultures when treated for 72 hours with FK866 (Figure 5.3 a). 
It can be seen that the viability decreases to 78.18% when treated with 300 nM FK866 
(p= <0.05) in MCF-7 cell lines however the MDA-MB-231 cell line shows a decrease to 
62.92% when treating with 100 nM FK866 (p= <0.05). Although this shows slightly 
different results to the MTT assay (Chapter 4), where there was a decrease in effect 
from 10 nM, there is an effect on cell viability. The difference could be due to MTT 
measuring vitality as opposed to viability. The vitality measured the activity of the 
mitochondria within the cells whereas viability is the determination of living cells 
based on a total cell sample. Therefore there is an effect on the activity of the 
mitochondria within the cells from 10 nM FK866 however there is not an effect on the 
number of living cells until 100 nM FK866. 
The cell viability in spheroid cultures was measured and calculated as percentage of 
the control (Figure 5.3 b). Although the MCF-7 cells seem to show some increase when 
treated with lower concentrations of FK866, increasing to 202.95% when treated with 
1 nM FK866 (p=<0.05) it decreases to 66.72% when treating with 300 nM FK866 
(p=>0.05). The MDA-MB-231 cells also show a decrease in cell viability with a gradual 
decrease to 39.35% when treating with 300 nM FK866 (p=<0.05). When comparing this 
to the monolayer culture there does appear to be an increased effect on cell viability 
when treating spheroids than monolayers. The effects of FK866 in spheroids decrease 
by 11.46% compared to the monolayers and MDA-MB-231 see a decrease in cell 
viability by 23.57% when compared to monolayer cells. This shows that the cells grown 
in spheroid are more susceptible to the Nampt inhibitor which could be due to 
increases in cell to cell interactions in spheroid cultures. 
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Figure 5.4: The effect on cell viability of MDA-MB-231 and MCF-7 cell lines when treating with Olaparib 
using the APH assay. A) shows the results of this in MDA-MB-231 and MCF-7 cells grown in monolayer 
(number of individual experiments = 3; number of repeated per experiment =2) and b) shows the results 
of these cells grown in spheroid culture (number of individual experiments = 4; number of repeats = 5). 
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Both breast cancer cell lines were grown in monolayers and treated with varying 
concentrations of Olaparib, a PARP-1 and 2 inhibitor, for 72 hours before the cell 
viability was measured (Figure 5.4 a). The cell viability in MDA-MB-231 cells show an 
increase in cell viability when treating with lower concentrations of FK866 however the 
cell viability decreases to 31.82% when treating with 100 µM Olaparib (p=<0.05). The 
MCF-7 cells show very little change in cell viability until treated with higher 
concentrations where the cell viability decreases to 43.43% of the control when 
treated with 100 µM Olaparib (p=<0.05). This indicates that only higher doses of 
Olaparib have an effect on decreasing the cell viability of cells grown in monolayer. 
The spheroids were treated with varying concentrations of Olaparib from 100 nM to 
100 µM for 72 hours before the cell viability was measured as a percentage of the 
control (Figure 5.4 b). When treating with lower concentrations, the MCF-7 cell line 
shows some increase in cell viability. This decreases to 92.14% of the control when 
treating with 30 µM of Olaparib (p=>0.05). The MDA-MB-231 also shows an increase in 
cell viability when treating with the lower concentrations of Olaparib which begins to 
decrease at higher concentrations to 104.38% when treating with 100 µM Olaparib 
(p=>0.05). When comparing the cell viability of cells grown in spheroid culture to the 
cell viability in monolayers there is an increase in cell viability in both cell lines with an 
increase of 72.56% in MDA-MB-231 cells and an increase of 48.71% in MCF-7 cells. This 
indicates that although Olaparib has an effect on the cells grown in monolayer at 
higher concentrations of Olaparib, the spheroids do not show an effect. This could be 
due to the increase in cell to cell interactions that are seen when cells are grown in 3D 
culture (Grimes et al., 2014; Knight and Przyborski 2015). From the trends seen in 
these results it could be possible that if the cells were treated with higher doses than 
were investigated here, then there could be some effect on the cell viability. 
 
5.2.2 NAD+ Concentrations 
After measuring the cell viability in both monolayer and spheroids for both cell lines, 
the NAD+ levels were measured to analyse whether there is any difference in how the 
treatments affect the NAD+ levels between the different methods of cell culture. 
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Figure 5.5: The NAD
+
 levels were measured in FK866 treated MD-MB-231 and MCF-7 cells. A) shows the 
effects of FK866 on NAD
+
 in the cells grown in monolayer and b) shows the effects of FK866 on NAD
+
 on 
the cells grown in spheroid cultures (number of individual experiments = 3; number of repeats per 
experiment = 5) 
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The NAD+ levels were measured in both MDA-MB-231 and MCF-7 cell lines which were 
treated with varying concentrations of FK866 and grown in monolayer after 72 hours 
(Figure 5.5 a). The MDA-MB-231 cell line shows an increase in the NAD+ levels to 98.49% 
when treated with 3 nM before decreasing to 69.60% when treating with 300 nM 
FK866 (p=<0.05). The MCF-7 cell line shows a greater decrease to 52.41% of the 
control when treating with 300 nM FK866 (p=<0.05). It can be seen that over the 72 
hours the NAD+ levels decrease which corresponds to the results seen in previous 
chapters (Chapter 3). This correlates to the decrease in the cell viability, as when the 
NAD+ levels decrease, the cell viability also seems to decrease which is to be expected 
with this treatment. 
The volumes of the spheroids were calculated in µm3 before the NAD+ concentrations 
were calculated as a percentage of the control (Figure 5.5 b). The MDA-MB-231 cells 
treated with lower concentrations of FK866 whilst grown in spheroids show an 
increase in NAD+ levels however; this begins to decrease at the higher concentrations 
to 70.95% when treating with 300 nM FK866 (p=>0.05). When compared to the 
monolayer the NAD+ levels decrease to a similar percentage of control with the 300 
nM however; when treated with lower concentrations there seems to be more of an 
effect on depletion of NAD+ levels in the monolayer than in the spheroid cultures. This 
indicates that the lower concentrations have an effect on NAD+ levels in monolayer 
whereas the spheroid cultures require the higher concentration of FK866. The MCF-7 
cells show a decrease in NAD+ levels to 68.27% when treating with 100 nM FK866 
(p=<0.05). The monolayer shows a greater decrease in the NAD+ levels when compared 
to spheroid cultures which indicates that the treatment has less of an effect on 
spheroid culture until higher concentrations. Both cell lines seem to show similar 
effects in both the cell viability and the NAD+ levels. This correlates with the hypothesis 
that when growing cells in spheroid culture, the lower concentrations of FK866 seem 
to have little effect on the viability and NAD+ levels which could be due to the cell to 
cell interactions which could interfere with the uptake of the treatments in the cells 
whereas the monolayer is more susceptible to this treatment as it has a different 
morphology and lacks some cell to cell interactions. The NAD+ levels were then 
measured in spheroid and monolayer cultures which were treated with the PARP 
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inhibitor Olaparib to determine what the results of inhibition with an NAD+ utilising 
enzyme. 
 
Figure 5.6: MDA-MB-231 and MCF-7 cells lines grown in monolayer (a) and spheroid (b) culture which 
have been treated with varying concentrations of Olaparib and the NAD
+
 levels were measured (number 
of individual experiments = 3; number of repeats per experiment = 5). 
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MDA-MB-231 and MCF-7 cells were grown in monolayer before being treated with 
varying concentrations of Olaparib from 100 nM to 100 µM to show how the NAD+ 
levels vary in this range (Figure 5.6 a). The MCF-7 cells show some increase in NAD+ 
levels to 180.09% when treating with 30 µM Olaparib (p=<0.05). The MDA-MB-231 
cells also show an increase in NAD+ levels to 362.76% when treating with 100 µM 
Olaparib (p=<0.05). Therefore the NAD+ levels increase alongside increasing 
concentrations of Olaparib. This could be due to the inhibition of the NAD+ consuming 
enzymes PARP-1 and 2 which therefore increases the NAD+ concentration within the 
cells. When comparing this to the cell viability it seems that as the NAD+ levels increase 
the cell viability decreases, this seems to be a different trend to what has been seen in 
the FK866 treatments however; as Olaparib inhibits PARP-1 and 2, which are NAD+ 
consuming enzymes, this could explain the reason for the increase in NAD+ levels. By 
inhibiting PARP this prevents the repair of DNA causing the cells to go through 
apoptosis and therefore decreasing the cell viability. 
MDA-MB-231 and MCF-7 cells where grown in spheroids and treated with Olaparib for 
72 hours (Figure 5.6 b). When MDA-MB-231 cells were treated with the lower 
concentrations of Olaparib the NAD+ levels begin to show some decrease to 63.86% of 
the control when treated with 1 µM (p=<0.05) however with the higher concentrations 
the NAD+ levels increase to 123.38% of the control when treated with 100 µM Olaparib 
(p=>0.05). The MCF-7 cells also show a decrease in NAD+ levels when treated with 
lower concentrations of Olaparib to 74.10% when treated with 1 µM increasing to 
130.06% when treating with 100 µM Olaparib (p=>0.05). When looking at the trends in 
the monolayer culture data, this correlates with the cell viability results whereby the 
cell viability increases at lower concentrations of treatment however it begins to 
decrease after being treated with the higher concentrations. When compared to the 
levels seen in the monolayer again it correlates with the cell viability showing that the 
increase in NAD+ levels is not as high as the increase in monolayer which indicates that 
the cells grown in spheroid culture are not responding as well to the treatment as the 
cells grown in monolayer. 
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5.3 Discussion 
Traditional methods of cell culture are centred on growing cells in a monolayer for 
their ability to adhere to treated plastics. These cells are easy to grow and maintain as 
well as straightforward to manipulate however; they lack the complexity of a solid 
tumour (Nagelkerke et al., 2013). Some of the environmental conditions observed in 
solid tumours can be artificially replicated into cultures, such as hypoxia and nutrient 
deficiency (Nagelkerke et al.,2013). 3D cultures are now being used to study different 
areas of cellular biology such as metabolism, apoptosis, proliferation and metastasis 
(Mullen-Klieser 1997; Kunz-Schughart 2004; Hirschhaeuser et al., 2010). The cells at 
the centre of the spheroid suffer from a lack of oxygen therefore making them hypoxic 
similar to solid tumour cells in vivo. In this chapter, 3D cell culture models were 
compared to monolayers and treated with FK866 (Nampt inhibitor) or Olaparib (PARP-
1 and 2 inhibitor). The effects of these treatments were investigated by measuring the 
cell viability and NAD+ levels to assess if there is a difference between the different 
methods of cell culture and their response to these treatments. 
FK866 is a Nampt inhibitor which decreases the NAD+ levels and therefore should 
reduce glycolysis (see Chapter 3) as well as other mechanisms such as DNA repair. 
During the investigations presented in this chapter, the monolayer and spheroid 
cultures seemed to have display similar responses when treated with FK866, although 
no response was seen in the spheroid culture until the higher concentration 
treatments. This is because as a single layer of cells, such as the monolayer, the 
treatments can easily affect the cells biochemical processes, however once the cells 
are in spheroid form they display more characteristics similar to that of in vivo tumour 
cells. Therefore a treatment which is effective on a monolayer culture may not exhibit 
the same effect on spheroid and animal models (Knight and Przyborski 2015). From the 
results presented in this chapter, it can be concluded that FK866 does have an effect 
on cells in spheroid although it requires a higher concentration of FK866 to achieve this 
result. This could be due to lower concentrations being unable to penetrate the 
hypoxic cells in the centre of the spheroid (Grimes et al., 2014) however at this stage 
this is as hypothetical explanation of the results. 
81 
 
Olaparib is a PARP-1 and 2 inhibitor which shows inhibition in micromolar 
concentrations. By inhibiting PARP, the repair of single strand breaks is also inhibited. 
Due to this, DNA forks are produced which then increases the likelihood of the 
development of double stranded breaks therefore leading to cell death via apoptosis 
(Shaw and Hall 2013).The results of this study show that there was some effect on 
both cell lines, however the effects of this treatment were more prevalent in the 
monolayer culture as opposed to the spheroid culture. As with the FK866 treatments 
this indicates that the lower concentrations of Olaparib are assumed to be unable to 
penetrate the hypoxic cells at the centre of the spheroid, potentially be due to the 
increased cell to cell interactions which are not seen in monolayer. Therefore it is likely 
to be necessary to treat the spheroid cultures with higher doses and/or longer 
treatment times, of Olaparib to achieve similar results to those seen at lower 
concentrations in monolayers.  
During drug trials, many treatments seem to fail when they progress from monolayer 
cell culture to animal models (Grimes et al., 2014; Raghaven et al., 2016). By using 3D 
culture as an intermediate step between these phases, there is more accurate 
information on how the treatments are likely to work in solid tumours. This is because 
their metabolic profiles as well as signalling and cell to cell interactions are similar to 
that of in vivo cells (Hirschhaeuser et al., 2010; Grimes et al., 2014). FK866 treatment 
of spheroids showed similar results to the monolayer albeit requiring a higher 
concentration to achieve the same level of effect. It would therefore be useful to 
continue this line of investigation with a combination of treatments similar to that of 
Chapter 4 to investigate whether there would be a similar effect with the cells grown 
in spheroid culture opposed to monolayer. Olaparib shows that the effectiveness of 
the treatment decreases as the model is changed from monolayer to spheroid. This 
could indicate that this treatment is not as effective as first thought, however the next 
step of this study would be to either increase concentrations, as examination of the 
data shows that higher concentrations than initially investigated could be more 
effective, or increase the treatment over 5 days or possibly even 15 days similar to the 
co-therapy work conducted by Bajrami et al., 2013.  
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Chapter 6: General Discussion and 
conclusions 
NAD+ is a co-enzyme which is found in all living cells as a carrier of electrons during 
redox reactions. It is most commonly known for the role it plays in glycolysis, however 
it is also plays a part in other pathways such as DNA repair and the deacetylation of 
histones. The recycling of NAD+ involves the enzyme Nampt which converts NAM to 
NMN before being converted to NAD+ via the NMNAT enzyme. Nampt has been seen 
to be up-regulated in some cancerous cells (Hasmann and Schemainda 2003). Nampt 
has become a target enzyme for chemotherapy treatments as it has been shown to be 
a pre-B-cell colony-enhancing factor (PBEF), as well as a poor prognostic marker when 
overexpressed in patients receiving doxorubicin-based chemotherapy for breast cancer 
(Hufton et al., 1999; van Beijnum et al., 2002; Folgueira et al., 2005). One treatment 
that has been developed to target Nampt is FK866. The overarching aim of this project 
was to investigate the mechanisms and therapeutic characteristics of FK866 as these 
remain poorly understood at this time. In addition to this, it was hypothesised that by 
decreasing the NAD+ levels (and thus ATP concentrations), FK866 will increase the 
efficacy of drugs that normally compete with ATP/NAD+ for binding sites on targeting 
enzymes (e.g. PARP and Sirtuins) and thus may have a role as a co-therapy strategy to 
increase the efficacy of many current and new chemotherapy agents. 
Chemotherapy treatments aim to incite a range of processes such as DNA damage, ATP 
depletion and apoptosis via the apoptotic biochemical cascade, all with the intention 
of causing cell death in cancerous cells. FK866 was first synthesised in 2003 (Hasmann 
and Schmeinda 2003) and fits into all the requirements of a chemotherapy treatment 
since it has a low molecular weight and decreases intracellular NAD+, which should 
theoretically should lead to cell death. FK866 interacts with the active site of Nampt 
and directly competes with nicotinamide for the binding site. It could therefore be 
used as a chemotherapy agent as published research suggests tumour cells are more 
susceptible to the inhibition of NAD+ biosynthesis than healthy cells (Hasmann and 
Schmeinda 2003; Wosikowski et al., 2002; Holen et al., 2008). FK866 is not known to 
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be subject to common mechanisms involved in multidrug resistance, as its activity is 
not cell cycle dependent (Holen et al., 2008). It has been shown to have high anti-
tumour activity in a wide variety of tumour cells, from solid tumours and leukaemias in 
vitro to a large number of human xenografts in nude mice and rats (Holen et al., 2008). 
FK866 has been shown to cause delayed cell death which indicate autophagy 
(Billington et al., 2008). 
It was found that as a single agent FK866 decreases the cell vitality, NAD+ levels and 
glycolytic activity. NAD+ is consumed by 3 enzymes, PARP, CD38 and Sirtuins. It was 
found in this project that when inhibiting Nampt, all three enzymes are involved in 
NAD+ consumption, however in the breast cancer cell line, MDA-MB-231; Sirtuins were 
the main consuming enzyme when Nampt was inhibited. When pre-treating the cells 
with FK866 before treatments with NAD+ consuming enzyme inhibitors, it was shown 
that there was a non-significant increase in the cell vitality in the cells after pre-
treatment with FK866 prior to treatment with an NAD+ consuming enzyme inhibitor or 
methylating agent however there was a decrease in the NAD+ levels. 
Otto Warburg conducted experiments into the connection between the production of 
lactic acid and the rate at which oxygen was consumed in healthy and tumour cells. He 
found that although both cell types produced a similar amount of ATP, healthy cells 
consumed higher levels of oxygen in cancer cells as well as showing an increase in 
lactic acid (Warburg 1956). This is now commonly known as the Warburg effect. With 
FK866 inhibiting the biosynthesis of NAD+, the oxygen consumption rates were 
measured in both MDA-MB-231 and MCF-7 cell lines, it was found that FK866 does not 
have any significant effect on oxygen consumption. Nicotinamide has been previously 
shown to partially protect oxidative phosphorylation however this was found to not be 
dose-dependent. The cells treated were also unable to recover after the oxidative 
damage which indicates some protection of glycolysis (Rovito and Oblong 2013). 
It is believed that an increase in glycolytic activity can be caused by mitochondria in 
tumour cells, which show signs of having impaired respiration (Moreno-Sanchez et 
al.,2014). Cells that are found on the outer layer of a tumour divide faster than those 
found in the centre of the tumour, therefore they are more likely to produce ATP via 
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oxidative phosphorylation whereas the hypoxic cells at the centre of the tumour rely 
more on glycolysis to produce ATP (Wallace 2005; Wu et al., 2007). Whilst cells are 
treated with oligomycin they the need to tap into glycolysis to achieve the ATP 
generation required (Nickens et al., 2013). This can be seen in all the samples during 
this study where there was an increase in glycolytic activity from basal levels after 
treatment with oligomycin. Over the varying concentrations of FK866 used, it was seen 
that there was a general increase in glucose stimulated extracellular acidification rate 
(ECAR), and stimulation of oligomycin was up to 100 nM FK866. Even with this there 
was no significant change in the spare glycolytic capacity and non-glycolytic ECAR. This 
indicates that the lower concentrations of FK866 seem to increase the activity of 
glycolysis however; at the higher concentrations a decrease in activity of glycolysis was 
observed.  
The production of ATP and the catabolic metabolism can be connected via the 
NAD+:NADH redox state, which indicates that low levels of NAD+ can limit the energy 
production within cells. During this study the NAD+:NADH+ ratio was measured using 
the NAD+ cycling and NADH cycling assay. The NAD+ and NADH were measured with 
varying concentrations of FK866 over 24 hours. In the MDA-MB-231 cells, FK866 does 
exhibit some effect on the NAD+:NADH ratio, whereas there was no observed change 
in the MCF-7 cells. The depletion of the NAD+:NADH ratio by FK866 may indicate some 
cytotoxicity in the MDA-MB-231; however the increase in glycolysis at lower 
concentrations may indicate an increase in cell vitality. The NAD+:NADH ratio is linked 
to the ratio of lactate and pyruvate within cells due to the local lactate production. The 
lactate production results from the decrease in oxygen availability and increase in 
glycolysis (Wilhelm and Hirrlinger 2012). 
Although NAD+ is used in glycolysis it is also utilised by other enzymes in different 
biochemical processes within the cell such as DNA repair as well as NAD+ dependent 
protein deacetylation. These enzymes include PARP, Sirtuins and CD38. PARP-1 cleaves 
NAD+ and forms large, negatively charged PAR molecules. NAD+ and ATP depletion by 
PARP-1 can be protected by inhibiting PARP-1 (Bakondi et al., 2004; Erdelyi et al., 2009; 
Canto et al., 2013). Clinically PARP inhibitors could have potential as therapeutic 
agents and there is evidence to suggest that they are selective for tumours with 
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recombination gene defects like BRCA 1 and BRCA 2 mutations. This means that some 
of these inhibitors could be useful as single agents. When measuring NAD+ levels after 
8 hours of treatment with PARP-1 inhibitor, NPH, and FK866 MDA-MB-231 cells show a 
small decrease in the NAD+ levels when compared to FK866 alone. This indicates that 
in the MDA-MB-231, although it was originally thought to be a main consumer of NAD+, 
it appears that PARP-1 is not the main consumer in this cell line. The reason that the 
MDA-MB-231 show little change could be due to the fact that PARP-1 and PARP-2 have 
similar uses and when one is inhibited the other replaces it (Steffen et al., 2013). 
Sirtuins are enzymes which are involved in the regulation of metabolism (Cui et al., 
2015). Sirt1 uses NAD+ to produce NAM as well as O-acetyl-ADP-ribose when the acetyl 
molecules are removed from lysine residues. It was hypothesised that sirtuins would 
be an NAD+ consuming enzymes however were not thought to be the main consumer 
in MDA-MB-231 cells. It was seen that there was no change in the NAD+ consumption 
when the cells were treated with FK866 and Sirtinol when compared to the control 
which indicates that Sirt1 is the main consumer of NAD+ whilst inhibiting Nampt. It has 
been seen in most breast cancer cell lines that Sirt1 expression can be linked to 
metastasis and poor prognosis (Chung et al., 2015), this would indicate that Sirt1 plays 
a more important role in breast cancer than originally thought and therefore would 
explain why when inhibiting Nampt and Sirt1 seems to be completely reverse the 
effects of Nampt inhibition with FK866, returning to the control levels. CD38 is a NAD+ 
glycohydrolase and is a widely used negative prognostic marker by clinicians in chronic 
lymphocytic lymphoma (CLL), as it is expressed on the surface of CLL cells (Vaissitti et 
al., 2011). It was unclear what to expect in terms of the results regarding MDA-MB-231 
whilst inhibiting CD38 as it is unknown whether this cell line expresses CD38. However 
when combining the Kuromanin and FK866 treatments there was some increase in 
NAD+ levels when compared to FK866 alone. This gives some indication that there is 
CD38 present although it could be that Kuromanin is having some other effect on 
these cells. To prove the presence of CD38 it may by useful to complete further 
analysis for example PCR.  
As FK866 has an effect on NAD+ levels after 8 hours, it was hypothesised that there 
would be a synergistic effect when pre-treating cells with FK866 prior to treatment 
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with NPH, Olaparib, Sirtinol or Temozolomide. MCF-7 cells showed a general increase 
in cell vitality after treating with NPH and Olaparib after 48 hours whereas the MDA-
MB-231 cells showed an increase with these treatments of this time point. When 
treated for 72 hours the cell vitality decrease compared to the 48 hour treatment 
however the Olaparib treatment shows an initial increase but at higher concentrations 
seem to decrease to similar levels compared to the control in both MDA-MB-231 and 
MCF-7 cells. After 72 hours the NAD+ seems to decrease over varying concentrations of 
both Olaparib and NPH although the MAD-MB-231 seem to show some increase after 
treating with higher concentrations of NPH. This data would suggest that both 
treatments seem to have an effect on the cell lines; however NPH has more of an 
effect on the cell vitality. This is due to both NPH and Olaparib being inhibitors of PARP. 
As there seems to be more of a decrease in NAD+ levels when treating with Olaparib 
than with NPH this could be due to the inhibition of both PARP-1 and PARP-2. This is 
similar results to that published by Bajrami et al, 2012 where they report sensitivity to 
Olaparib with increasing concentrations of FK866. MDA-MB-231 showed that Sirt1 was 
a main consumer of NAD+ whilst inhibiting Nampt with FK866 for 8 hours however 
when treating the cells for 48 and 72 hours the cell vitality increased as the NAD+ levels 
decreased. As there is a connection with Sirt1 and poor prognosis in breast cancer cells, 
this confirms the results seen with the increase in cell vitality (Hiraike et al., 2011; Yuan 
et al., 2013; Chung et al., 2015).The lack of effect on the cell vitality in MDA-MB-231 
cells could be due to the cells being triple negative as they have no estrogen receptor α 
which requires Sirt1 (Yuan et al., 2013). Temozolomide is a DNA methylating agent 
which binds to the DNA, primarily guanine, and results in the single stranded DNA 
breaks (Horton et al., 2009).The treatment of Temozolomide with a pre-treatment of 
FK866 showed a general increase in cell vitality in both cell lines over 48 and 72 hours. 
There is also an increase in NAD+ levels although Temozolomide has not been shown to 
have an effect on NAD+ utilising or synthesising enzymes. This change in NAD+ levels 
could be due to PARP levels being increased in response to DNA damage although this 
has not been proven, performing a western blot may help in this aspect. Although 
some results from this study would indicate a positive response overall it can be seen 
that this is not a viable method of treatment with these cells. Potentially a different 
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approach or longer incubations would be a more viable approach to analysis this 
further. 
Both the studies presented in Chapters 3 and 4 made use of monolayer cell cultures. A 
new method has been developed in recent years for the use of 3D cell culture, 
whereby the cells are grown in spheroid as seen in Figure 5.1 as opposed to the single 
layer of cells characteristic of monolayer cultures. Monolayers lack the functionality 
seen in tumour cells in vivo due to their flat and stretched morphology, which is 
physically dissimilar to tumour cells, and their lack of cell to cell interactions which 
makes them more susceptible to cytotoxic effects (Nagelkerke et al., 2013). Spheroid 
culture is therefore a valuable substitute which will provide a more accurate insight 
into the tumour response when treated with therapeutic agents, giving a similar 
response to that seen in vivo. (Dufau et al., 2012). When both monolayer and spheroid 
cultures were treated with FK866, they showed similar effects in both cell lines, 
although the spheroid culture required a higher concentration of FK866. It was 
expected that the spheroid cultures would be slightly less responsive than the 
monolayers because as mentioned, monolayer morphology means it is easier for the 
treatment to have an effect on the biochemical processes, however when in spheroid 
form they share more characteristics, typically seen in in vivo tumour cells (Knight and 
Przyborski 2015). When the cell lines were grown both in monolayer and spheroid 
cultures before being treated with Olaparib it was seen that although there was some 
effects on both cell lines there was more pronounced effect seen in the monolayer. 
Both treatments require higher concentrations when treating spheroid culture which 
would indicate that the morphology of the spheroid are harder to penetrate, resulting 
in higher treatment concentrations to incite a response in particular this could be due 
to the hypoxic cells at the centre of the spheroid, as well as the increase in cell to cell 
interactions which are not seen in monolayer cultures (Hirschaeuser et al., 2010; 
Grimes et al., 2014). 
6.1 Conclusions 
This project has investigated the characterisation of the pharmacological mechanisms 
and potential therapeutic uses of FK866. It was hypothesised that the decreasing 
intracellular NAD+ levels can be used as a co-therapy strategy to increase the efficacy 
88 
 
of current and new chemotherapy treatments. By decreasing NAD+, and thus ATP 
production and availability, the concentrations will increase the efficacy of the 
treatments that would normally compete for ATP/NAD+ binding sites on targeting 
enzymes (e.g. PARP and sirtuins). Therefore by inhibiting NAD+ levels and treating with 
current chemotherapeutics, there will be a higher level of cellular cytotoxicity. FK866 
as a single treatment has been shown in this study to have an effect on cell viability, 
NAD+ levels and glycolytic activity in breast cancer cell lines, although the effects on 
glycolytic activity were not significant. The effects seen on the cell viability and NAD+ 
levels were seen in both monolayer and spheroid cultures which indicates that this 
treatment, although requiring higher concentrations in the spheroid cultures, could 
illicit beneficial responses in in vivo investigations. When combining the treatments it 
was found that Sirt1 is the main consumer of NAD+ whilst inhibiting Nampt in MDA-
MB-231 cell line although CD38 and PARP-1 also play a smaller role in NAD+ 
consumption. When the MCF-7 and MDA-MB-231 cells were pre-treated with FK866 
before being treated with current chemotherapeutics such as Temozolomide or NAD+ 
consuming enzyme inhibitors such as NPH, Olaparib and Sirtinol it was seen that after 
72 hours of treatment there was a small increase in cell vitality in most treatments 
with the exceptions of MCF-7 showing a decrease when treating with NPH. The NAD+ 
levels however seemed to show a general decrease excluding the cells treated with 
Temozolomide which is expected as Temozolomide has not been known to have an 
effect on NAD+ levels. The trends that were seen between the 48 and 72 hours indicate 
that potentially longer exposure to the treatments may result in a decrease in cell 
vitality From the results of each chapter seen in this investigation it can be concluded 
that FK866, as a single agent exhibits some degree of therapeutic effect as well as 
having an effect on cellular mechanisms. However as a pre-treatment this is not a 
viable treatment in terms of these cell lines. Therefore FK866 does not have a use in 
therapeutic treatments. 
6.2 Future Work 
Results from the present study have highlighted a number of areas for further 
investigation. For example, the Seahorse measurements in spheroid and with co-
therapy would be useful as this would give a greater insight into the oxygen 
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consumption dynamics and glycolytic activities under these conditions. So far there has 
not been a significant amount of studies using the SEAHORSE assay in spheroid 
cultures however methods are being developed for this in different areas of research 
for example diabetic research. It would also be of interest to determine the effect on 
cell vitality if co-treatment times were increased beyond those utilised in this study, 
akin to the work of Bajrami et al.,2012. That study, showed that after 15 days there 
was a decrease in cell viability. By default I feel it would also be necessary to repeat 
this with a pre-treatment with NAD+ to see if increasing the concentration of 
extracellular NAD+ has any effect on the cells with PARP and sirtuin inhibitors. When 
analysing the results presented in Chapter 3, MDA-MB-231 cells showed some 
inhibition of NAD+ consumption when treating with FK866 and Kuromanin, a CD38 
inhibitor, which could indicate that there is CD38 present in these cells. It is normally 
associated with leukaemia cells however it could potentially be possible for it to be 
present in these cells, therefore by performing PCR on these cells it will determine 
whether or not there is any presence of this enzyme. If this is not the case then 
potentially Kuromanin is reacting with another enzyme within these cells and it could 
be of interest to determine what this is. Spheroid cell culture would appear to offer an 
effective new method for drug analysis in a cell culture relevant to the ultimately 
intended target (in vivo tumour cells) and would be interesting to take this FK866 
research further with cell lines grown in spheroid culture. This would include repeating 
the experiments conducted in Chapter 4 but with the cell lines growing in spheroid 
culture. Measuring the glycolysis in spheroids would be advantageous although the 
Seahorse is a relatively new machine and the methods used to measure oxidative 
stress and glycolytic activity have so far been with mainly adherent cells. Recent 
development work by Seahorse Biosciences has resulted in plates for islet capture 
however they have not guaranteed that these would work with spheroid culture and 
therefore would be difficult to get a working protocol. They are however making huge 
advances in this technology so hopefully in the future this will be possible. Although 
this procedure would be ideal in the future it can also be expensive to run as at the 
moment the islet capture plates are more expensive than monolayer plates. It would 
also be useful to take this research into more cell lines of breast cancer and also into 
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ovarian cancer as the BRCA gene and PARP activity are important in both types of cell 
and the PARP activity with BRCA mutations rely on NAD+ for DNA repair. 
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